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ABSTRACT 
 
Recent evidence indicate that small non-coding RNA molecules, called 
micro-RNAs (miRNA), can bind to the 3’UTRs of mRNAs and interfere with their 
translation, thereby regulating cell growth, differentiation, apoptosis, and 
tumorigenesis. Genetic polymorphisms can reside on miRNA binding sites. 
Thus, it is conceivable that the miRNA regulation may be affected by 
polymorphisms on the 3’ UTRs. Since gene de-regulation is one of the key 
mechanisms by which cells can progress to cancer, we hypothesize that 
common polymorphisms within miRNA target binding sites could play a role in 
the individual risk of cancer.  
In the present study, we selected the 3’UTR regions of 129 genes candidate 
for colorectal cancer (CRC) and we identified putative miRNA binding sites by 
specialized algorithms (PicTar, DianaMicroT, miRBase, miRanda, TargetScan, 
and microInspector). We evaluated the SNPs for their ability to affect the 
binding of the miRNA with its target, by assessing the variation of Gibbs free 
energy between the two alleles of each SNP. We found 15 common 
polymorphisms. We added to this list 8 SNPs in miRNA sequences. All the 
polymorphisms were further investigated by a case-control association studies. 
The study was carried out on a series of cases and controls from Czech 
Republic, a population with the highest worldwide incidence of CRC. We found 
statistically significant associations between risk of CRC and variant alleles of 
CD86 (OR=2.74 95%CI=1.24-6.04, for the variant homozygotes) and INSR 
genes (OR=1.94; 95%CI=1.03-3.66, for the variant homozygotes).  
 5 
Then, these two polymorphisms were genotyped in three different 
populations: Spanish, Italian, and German.The statistical analyses for all the 
samples (Czech, Spanish, Italian, and German) confirmed the assciation 
between risk of CRC and the polymorphisms in CD86 and INSR. These results 
are the first reporting positive association between miRNA-binding SNPs 
sequences and cancer risk. 
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1. INTRODUCTION 
 
1.1. MicroRNA 
1.1.1. What is a microRNA? 
MicroRNAs (miRNAs) are endogenous non-coding RNAs of about 22 
nucleotides, regulating genes in animals and plants by pairing to the 3’UTR 
regions of messenger RNAs (Zeng et al., 2002) of target genes and specifying 
mRNA cleavage or repression of protein synthesis. There is increasing 
evidence that miRNAs have an important regulatory role in a broad range of 
biological processes, including developmental timing, cellular differentiation, 
proliferation, apoptosis, cancer development, insulin secretion, and cholesterol 
biosynthesis (Bartel, 2004b). After the initial genetic discovery in nematodes 
(Lee et al., 1993a), it was soon confirmed that all investigated higher 
eukaryotes, including plants and mammals, contain miRNA genes (Ambros et 
al., 2003b). MiRNA genes represent only a small part of the genome (3%), but 
they regulate approximately from 20% to 30% of all human genes and there is 
an average of 200 predicted targets per miRNA (Carthew, 2006). 
 
1.1.2. MicroRNAs discovery 
This discovery has been an exciting breakthrough in Biological Sciences 
of the past decade, culminating in Nobel Prize in Physiology or Medicine 
awarded to Andrew Fire and Craig Mello. Building on previous work mainly in 
plants (Lindbo et al., 1993), Fire discovered that exogenous double-stranded 
RNA can be used to specifically interfere with gene function. This phenomenon 
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was called RNA interference (RNAi) (Fire et al., 1998). They also speculated 
that organisms might use double-stranded RNA naturally as a way of silencing 
genes. It was then shown that RNA interference was mediated by 22 nucleotide 
single-stranded RNAs termed small interfering RNAs (siRNAs) derived from the 
longer double-stranded RNA precursors (Zamore et al., 2000). Over the 
following years, many new small functional RNAs have been found. The first 
miRNA was discovered in 1993 by Victor Ambros and colleagues Rosalind Lee 
and Rhonda Feinbaum. A genetic screen in the groundworm Caenorhabditis 
elegans, a millimeter-long animal used as a model organism in biological 
research, identified genes involved in developmental timing (Lee et al., 1993b). 
Surprisingly, one of the genes, termed lin-4, did not encode a protein but 
instead a novel 22-nucleotide small RNA. Seven years later, Reinhart et al. 
discovered a second 22-nucleotide small RNA of this type, let-7, a gene also 
involved in C. elegans developmental timing.  
The homologs of the let-7 gene were identified in other animals including 
humans (Pasquinelli et al., 2000). The conservation of let-7 across species 
suggested an important and fundamental biological role for this small RNA.  
The mechanism of RNA interference (RNAi) was discovered at that time, 
and it became clear that miRNA and RNAi pathways were intricately linked and 
shared common components. Within the following year, more than 100 
additional small regulatory RNAs similar to lin-4 and let-7 were identified in 
worms, the fruit fly Drosophila, and in humans (Lee and Ambros, 2001). 
Subsequently, many more short regulatory RNAs were identified in almost all 
multicellular organisms, including flowering plants, worms, flies, fish, frogs, 
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mammals (Lim et al., 2003), and in single cellular algae and DNA viruses 
(Sullivan and Ganem, 2005).  
To date, more than 500 human miRNAs have been experimentally 
identified. Computational predictions of miRNA targets suggest that up to 30% 
of human protein coding genes may be regulated by miRNAs (Rajewsky, 
2006b). This makes miRNAs one of the most abundant classes of regulatory 
genes in humans. MicroRNAs are now perceived as a key layer of post-
transcriptional control within the networks of gene regulation. 
 
1.1.3. Genomic localization 
Micro-RNAs are initially transcribed as precursor molecules in the 
nucleus, where many are organized in genomic cluster, while others exist as 
individual genes. Besides miRNAs that are non linked to any other transcription 
unit, it has been reported that miRNA genes are located in exons or introns of 
non-coding genes (Rodriguez et al., 2004), as well as protein-coding genes 
(Smalheiser, 2003). It is not yet clear if these miRNAs are functionally related to 
their host genes, since the splicing machinery may not be able to release an 
intron that is accessible to further miRNA processing. On the other hand, 
splicing and miRNA processing might be coupled and miRNAs and their host 
mRNAs could be processed simultaneously. However, expression studies on 
miRNAs and host mRNAs revealed that miRNAs are frequently co-expressed 
with their host genes (Baskerville and Bartel, 2005). A sizable minority (e.g., 
about a quarter of the human miRNAs genes) are in the introns of pre-mRNAs. 
These are preferentially in the same orientation as the predicted mRNAs, 
suggesting that most of these miRNAs are not transcribed from their own 
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promoters but are instead processed from introns. This arrangement provides a 
convenient mechanism for the coordinated expression of a miRNA and a 
protein (Lagos-Quintana et al., 2003).  
Some mammalian miRNA genes are located in repetitive genomic 
regions as well, and it has been suggested that repetitive elements such as 
transposons may be the driving force that creates new miRNAs during 
mammalian evolution (Smalheiser and Torvik, 2005).  
MicroRNAs can be grouped into families on the basis of sequence 
homology, which is found primarily at the 5′ end of the mature miRNAs, but 
whether members of the same miRNA family control similar biological events 
remains to be seen. Many miRNAs are evolutionarily conserved from worms to 
humans, which implies that these miRNAs direct essential processes both 
during development and in the adult body (Esquela-Kerscher and Slack, 2006). 
 
1.1.4. MicroRNA biogenesis 
The maturation of microRNA is a multi-step process that begins in the 
nucleus and ends in the cytoplasm (Novina and Sharp, 2004) (figure 1). 
Analyses have shown that human primary miRNA transcripts (pri-miRNAs) 
contain cap structures as well as poly (A) tails which are the unique properties 
of class II gene transcripts. These data indicate that pol II is the main RNA 
polymerase for miRNA gene transcription (Lee et al., 2004). Moreover, in 2006, 
it was reported that ~ 50 human miRNAs are transcribed by RNA polymerase 
III. In fact, in a genomic analysis, the miRNAs in the human chromosome 19 
miRNA clusters were found to be dispersed among Alu repeats. Alu sequence 
is the most abundant transposable element in the human genome. It is derived 
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from the 7SL RNA gene, which encode the RNA component of the signal 
recognition particle that functions in protein synthesis. The Alu sequence 
contains the 7SL promoter, an RNA polymerase III promoter (Borchert et al., 
2006).  
Animal miRNAs are initially transcribed as part of a long RNA precursor, 
defined as “primary miRNA” (pri-miRNA). Within the pri-miRNA, the ~22-nt 
mature miRNA forms part of one arm of a ~80-nt imperfect stem-loop sequence 
(Cullen, 2004). The first step is the nuclear cleavage of the pri-miRNA, which 
liberates a ~60-70 nt stem loop intermediate, known as the miRNA precursor, or 
the pre-miRNA (Zeng, 2006). This processing is performed by Drosha, an 
RNase III-type endonuclease that contains two RNase III domains and a dsRNA 
binding domain in the C-terminal half, a proline-rich domain and an argininerich 
(R-rich) domain in the N-terminal half of the protein. It cleaves both strands of 
stem at sites near the base of the primary stem loop, leaving a 5’ phosphate 
and a 2-nt 3’ overhang (Basyuk et al., 2003). It has been demonstrated that for 
a pri-miRNA to be efficiently processed by Drosha the targeted hairpin must 
consist of a large terminal loop of ≥10 nt and a stem region somewhat longer 
than the one present in the final pre-miRNA (Zeng and Cullen, 2005). The class 
3 RNase III Drosha forms a complex (microprocessor) with a double-stranded 
RNA-binding protein, termed DGCR8 in humans and Pasha in flies and worms 
(Han et al., 2004). Cleavage of a pri-miRNA by microprocessor begins with 
DGCR8 recognizing the ssRNA-dsRNA junction typical of a pri-miRNA. Then, 
Drosha is brought close to its substrate through interaction with DGCR8 and 
cleaves the stem of a pri-miRNA ~11 nt away from the two single stranded 
segments (Han et al., 2006). Although microprocessor is already sufficient for 
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conversion of a pri-miRNA into a pre-miRNAs in vitro, cleavage of pri-miRNA in 
vivo does not depend on Drosha and DGCR8 only, but also on other accessory 
proteins, such as the RNA binding protein hnRNP A1 and the p68 and p72 RNA 
helicases. Gene-targeting experiments have demonstrated the importance of 
p68 and p72 for the biogenesis of a subset of mouse miRNAs. In p68 or p72 
knock-out embryos (knock-out of p68 in mice causes embryonic lethality while 
knock-out of p72 causes neonatal death), the expression of a subset of miRNAs 
is severely compromised. In another recent study, hnRNP A1 has been shown 
to be specifically required for the processing of pri-miR-18a in a context-
dependent manner (Fukuda et al., 2007; Guil and Caceres, 2007). In addition to 
the classical biogenesis pathway that depends on microprocessor, a subclass 
of pre-miRNAs, pre-miRNA/introns (mirtrons), have recently been shown to 
depend on the RNA splicing machinery for their biogenesis in Drosophila, 
Caenorhabditis elegans and mammals (Berezikov et al., 2007). Mirtrons are 
derived from certain debranched introns that fold into hairpin structures with 5′ 
monophosphates and 3′ 2-nt hydroxyl overhangs, which mimic the structural 
hallmarks of pre-miRNAs and enter the miRNA processing pathway (Okamura 
et al., 2007; Ruby et al., 2007). The discovery of mirtrons suggests that any 
RNA, with a size comparable to a pre-miRNA and all the structural features of a 
pre-miRNA, can be utilized by the miRNA processing machinery, and potentially 
give rise to a functional miRNA. 
After initial nuclear processing, the pre-miRNA is exported to the 
cytoplasm by the export receptor Exportin-5 (Exp-5). This step is a Ran-
dependent and requires the hydrolysis of GTP (Yi et al., 2003). Although 
Exportin-5 lacks a structurally known dsRNA-binding domain, it has been 
 12 
suggested that it interacts directly with the pre-miRNA. The interaction of 
Exportin-5 with the miRNA precursor requires a 3’ overhang and the stem of the 
precursor for efficient export (Zeng and Cullen, 2004). Exp-5 is also important 
for stabilizing pre-miRNAs in the nucleus. When Exp-5 is knocked down by 
siRNAs, the levels of pre-miRNAs are reduced not only in the cytoplasm, but 
also in the nucleus, suggesting that binding of pre-miRNAs to Exp-5 protects 
them from degradation (Yi et al., 2003).  
In the cytoplasm, another RNAse III endonuclease termed Dicer is 
responsible for dicing pre-miRNAs into short RNA duplexes termed miRNA 
duplexes (Bernstein et al., 2001). The RNA strand of the miRNA duplex that is 
complementary to the mature miRNA is depicted with a star symbol (miRNA*). 
In addition to two RNase III signature domains, mammalian Dicer has a N-
terminal ATPase/helicase domain, a DUF 283 domain, a PAZ domain and a C-
terminal dsRNA binding domain (dsRBD) (Provost et al., 2002). Biochemical 
experiments have revealed that both PAZ domain and dsRBD are essential for 
the interaction of Dicer with pre-miRNAs and long dsRNAs. PAZ domain 
functions in recognizing the 2-nt 3′ overhang signature generated by Drosha, 
while dsRBD is critical for binding long dsRNAs. After capturing pre-miRNAs or 
long dsRNAs with its PAZ domain and dsRBD, Dicer dimerizes its two RNase III 
domains intra-molecularly to form a single processing center, and cuts the stem 
of pre-miRNAs or long dsRNAs ~22 nt away from their termini at positions 
separated by 2 nts, which generates 3′ 2-nt termini (Zhang et al., 2004). In the 
case of long dsRNA, subsequent to the first cleavage, Dicer can use its PAZ 
domain to place it again at the termini of the dsRNA and dicer processively from 
the termini (Zhang et al., 2002). Although the functions of the C-terminal 
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domains of Dicer are clear now, the roles of the N-terminal ATPase/helicase 
domain and DUF 283 domain of Dicer still remain elusive. 
After Dicer processing, the miRNA duplex is unwound and the mature 
miRNA binds to an Argonaute (Ago) protein in a process that is referred to as 
miRNA loading or assembly, while the miRNA* is degraded. The Argonaute 
family is a diverse family of proteins, each containing characteristic domains 
termed PAZ and PIWI. The Argonaute family can be phylogenetically divided 
into the Ago and Piwi protein families based on similarities to Arabidopsis AGO1 
and Drosophila Piwi proteins, respectively (Carmell et al., 2002). miRNAs bind 
Ago proteins whereas Piwi proteins bind a newly discovered class of small 
RNAs known as piwi-interacting RNAs (piRNAs), which are almost exclusively 
expressed in the germline  (Aravin et al., 2007; Kim, 2006). Humans and mice 
contain four Ago proteins (Ago1–4). Structural and biochemical analyses have 
shown that the ~130- amino-acid PAZ domain contains an oligonucleotide-
binding fold that allows the protein to bind the single-stranded 2-nt 3′ terminal 
overhangs characteristic of small RNAs processed by Dicer (Lingel et al., 2004). 
The miRNA/Ago ribonucleoprotein that is formed represents the core 
component of the effector complexes that mediate miRNA function and is 
known as miRNP (Mourelatos et al., 2002). A primary determinant of which the 
two strands of a miRNA duplex or a siRNA duplex will be loaded on Ago 
proteins is the inherent thermodynamic asymmetry of the miRNA or siRNA 
duplex. The RNA strand whose 5′ end is less stably bound to the opposite 
strand will be loaded to Ago proteins and forms the mature miRNA or siRNA 
(Tomari and Zamore, 2005). Humans and other mammals contain a single 
Dicer gene and miRNP, and RISC assembly has many similarities but also 
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important differences to RISC assembly in flies. In humans, miRNP assembly is 
accomplished by a protein complex termed the miRNA RISC Loading Complex 
(miRLC). The miRLC is a multiprotein complex whose core components are 
Ago and Dicer proteins (Gregory et al., 2005).The miRLC is devoid of miRNAs 
and processes miRNAs from pre-miRNAs, and loads mature miRNAs to Ago 
proteins. The miRLC is then disassembled and the core miRNP (miRNA-Ago 
ribonucleoprotein) is generated (Maniataki and Mourelatos, 2005). However, the 
details of miRNP assembly in humans are unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: microRNA biogenesis (Novina and Sharp, 2004) 
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1.1.5. MicroRNA function 
MiRNAs base-pair with miRNA recognition elements (MREs) found in 
their mRNA targets (typically in the 3′ untranslated region-3′UTR) and deposit 
their bound Ago proteins onto mRNA targets. The result is translational 
repression of the targeted mRNA, often followed by mRNA destabilization or 
endonucleolytic cleavage of the targeted mRNA. The exact molecular function 
is dependent upon how extensive the complementarity of the miRNA or siRNA 
is with its mRNA target and which Ago protein is deposited on the mRNA target. 
If an miRNA or siRNA bound to Ago2 pairs with extensive complementarity with 
a cognate mRNA target, then the mRNA is cleaved at a position across from 
nucleotides 10 and 11 of the miRNA (or siRNA), while the miRNA remains intact 
(Figure 2) (Liu et al., 2004). This cleavage event produces 5′-phosphate and 3′-
hydroxyl terminal products, characteristic of other RNase H-like enzymes 
(Martinez and Tuschl, 2004).The target mRNA is subsequently degraded via 
routine cellular pathways (Figure 2). Target mRNA cleavage by miRNAs is the 
major mechanism of regulation by plant miRNAs (Dugas and Bartel, 2004). 
 
 
Figure 2: target RNA cleavage by Ago2-containing miRNP (Liu et al, 2007). 
 16 
In animals, however, there are very few examples of miRNAs that 
regulate their mRNA targets by cleavage (Yekta et al., 2004); rather, the 
predominant silencing mode of animal miRNAs is to repress the translation of 
their mRNA targets and/or to destabilize them without endonucleolytic cleavage 
(Filipowicz et al., 2005). Experimental and bioinformatics approaches have 
shown that the most important determinant of target RNA recognition by a 
miRNA is perfect or near-perfect complementarity between the proximal (5′) 
region of the miRNA and the mRNA, also known as the “seed” region or the 
“nucleus” (Figure 3) (Lai, 2002). Base-pairing between the 3′ portion of the 
miRNA and the mRNA target is not always essential for repression, but strong 
base-pairing within this region can partially compensate for weaker seed 
matches or enhance repression (Brennecke et al., 2005). Additionally, multiple 
MREs for the same, or different, miRNAs within the same 3′UTR can function 
cooperatively to enhance repression (Krek et al., 2005). Spacing of the seed 
sites within the 3′UTR may play a significant role in the cooperative action of 
miRNAs. Finally, sequences adjacent to MREs (Vella et al., 2004) and the 
secondary structure of the 3′UTR of the target mRNA affect binding of miRNAs. 
 
 
Figure 3: Principles of miRNA binding to target RNA (Liu et al, 2007) 
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Initial studies suggested that miRNA-mediated translational repression 
occurred at a step following the initiation of translation. This was based on the 
observation that, in C. elegans, lin-14 mRNA, a target of the lin-4 miRNA, could 
be found associated with mRNAs in polysomes, according to sucrose gradient 
sedimentation analysis (Seggerson et al., 2002). MiRNAs also associate with 
polysomes in both C. elegans and mammalian cells (Nelson et al., 2004). More 
recent studies have lent additional support to the model of miRNA mediated 
repression occurring at a post-initiation step (Petersen et al., 2006) (Figure 4).  
MiRNA mediated translational repression results in decreased levels of 
the targeted protein. Thus, the model of miRNA function occurring at a post-
initiation step would require the release of and subsequent destruction of the 
resulting polypeptide (Nottrott et al., 2006). 
 
 
Figure 4: Mechanism of repression of targeted mRNA by miRNPs (Liu et al, 2007) 
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A second model proposes that miRNA-mediated translational repression 
occurs at the initiation step (Figure 7B). Using human cells and reporter 
constructs targeted by either endogenous or exogenous miRNAs, two groups 
initially discovered that the m7G cap of an mRNA is required for efficient 
translational repression (Humphreys et al., 2005). MicroRNA-repressed 
messages sedimented in light fractions in polysome analyses, indicating that 
their translation was inhibited at the level of initiation (Pillai et al., 2005). 
 
1.1.6. MicroRNAs and siRNAs 
Important distinctions between miRNA and siRNA can be made, 
particularly in regard to their origin, evolutionary conservation, and the types of 
genes that they silencing.  
Infact, microRNAs derive from genomic loci distinct from other 
recognized genes and are processed from transcripts that can form local RNA 
hairpin structures, whereas siRNAs often derive from mRNAs, transposons, 
viruses, or heterochromatic DNA and are processed from long bimolecular RNA 
duplexes or extended hairpins. A single miRNA: miRNA* duplex is generated 
from each miRNA hairpin precursor molecule, on the contrary a multitude of 
siRNA duplexes are generated from each siRNA precursor molecule, leading to 
many different siRNAs accumulating from both strands of this extended dsRNA. 
Moreover, miRNA sequences are nearly always conserved in related 
organisms, whereas endogenous siRNA sequences are rarely conserved 
(Ambros et al., 2003a).  
Endogenous siRNAs typically specify “auto-silencing”, in that they specify 
the silencing of the same locus (or very similar loci) from which they originate, 
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whereas miRNAs specify “hetero-silencing”, in that they are produced from 
genes that specify the silencing of very different genes. Natural examples of 
auto-silencing include the silencing of virus, transposons, and the 
heterochromatic outer repeats of centromeres (Aravin et al., 2001). 
To the extent that the siRNAs come from the same loci that they target, a 
mutational event that changes the sequence of the siRNA would also change 
the sequence of its regulatory target, and siRNA regulation would be preserved. 
In contrast, a mutation in a miRNA would rarely be accompanied by 
simultaneous compensatory changes at the loci of its targets, and thus selection 
pressure would preserve the miRNA sequence (Bartel, 2004a).  
 
1.1.7. Polymorphisms and microRNA 
Single nucleotide polymorphisms (SNPs) are the most abundant form of 
DNA variation in the human genome and contribute to human phenotypic 
differences. Polymorphisms in miRNA genes could potentially alter various 
biological processes by influencing the processing and/or target selection of 
miRNAs. Duan and colleagues have identified 323 SNPs in 227 known miRNAs 
examined: 12 of these are located within the miRNA precursors. Interestingly, a 
polymorphism (G/U) was identified at the eighth nucleotide of mature miR-125a. 
This miR-125a SNP blocks the processing of pri-miRNA to pre-miRNA 
significantly in addition to reducing miRNA-mediated translational suppression. 
These data suggest that SNPs that reside within the miRNA genes could indeed 
regulate miRNA biogenesis and alter target selection, thereby potentially having 
profound biological effects (Duan et al., 2007). In the human genome, miR-125a 
is located at chromosome 19q13.41, a region that is frequently deleted in 
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primary gliomas, especially oligodendrogliomas (Law et al., 2005). Identified 
targets of miR-125a include Lin-28, Lin-41, ERBB2 and ERBB3. MiR-125a was 
found to be down-regulated in one breast cancer miRNA profiling study (Wu 
and Belasco, 2005).  
In a study of Iwai e Naraba, 173 human pre-miRNA genome regions in 
96 subjects were sequenced and 10 polymorphisms in 10 pre-miRNA hairpins 
were identified. Furthermore, a C to A polymorphisms in the mature miR-30c-2 
sequence was also identified. They showed that mature microRNA production 
was highly dependent on the integrity of the precursor RNA stem, although the 
underlying specific sequence had little effect. They also showed that the specific 
sequence of the terminal loop only moderately affected microRNA production 
(Iwai and Naraba, 2005).  
An association between microRNA-binding SNPs and the risk of common 
diseases was indicated in three different studies. In a landmark study, Abelson 
et al. (Abelson et al., 2005) showed that a SNP in the 3’UTR human SLITRK1 
gene strengthens an existing miR-189 target site, thereby amplifying the down-
regulation of SLITRK1, which is implicated in Tourette syndrome. Another study 
demonstrated that a 3’ UTR SNP in the sheep myostatin (Gdf8) gene creates a 
new illegitimate microRNA target site, which leads to the significant down-
regulation of Gdf8 and contributes to the development of muscular hypertrophy 
(Clop et al., 2006). In the third study, two groups almost simultaneously 
investigated the 3’ UTR of the human AGTR1 gene that contains the SNP 
rs5186 and showed that hsa-miR-155 specifically down-regulates the 
expression of only the 1166A, and not the 1166C, allele of rs5186 (Martin et al., 
2007; Sethupathy et al., 2007). Both groups concluded that, by abrogating the 
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regulation by miR-155, the 1166C allele may be functionally associated with 
hypertension and cardiovascular disease. 
 
1.1.8. Targets prediction and identification of new miRNAs 
In the past few years many computational methods to identify the targets 
of the miRNAs were developed. These methods search regions conserved in 
the 3'UTR that are complementary to the micro-RNA. The identification of the 
messengers target is more difficult in the animals than in the plants, because in 
the animals there are less mRNA perfectly complementary to the miRNA 
(Rajewsky, 2006a). The analysis of the binding sites of the miRNAs, that they 
must be validated experimentally, is based on more criteria: a perfect 
complementarity between the region 3'UTR of mRNA target and the first 8 
nucleotide of miRNA beginning from its extremity 5'UTR (inside of this region is 
admitted pairings G: U), the formation of a eteroduplex structurally and 
thermodynamically stable, and the evolutionary conservation of the sites target 
between the vertebrates (Brennecke et al., 2005). Several independent groups 
have formulated of the algorithms that serve to identify the targets of the miRNA 
(John et al., 2004). The binding of more miRNAs to the same messanger 
complicate the prediction of the targets (Krek et al., 2005).  
In several organisms hundred of miRNAs were identified and successively 
same studies were carried out on the profiles of genic expression (Krutzfeldt et 
al., 2006). Some characteristics allow to define if the identified molecule is a 
true one micro-RNA: a miRNA mature must be express as a transcript of 22 
nucleotides, derive from precursory with characteristic secondary structure 
(stem-loop structure), occupy the part of stem and be processed by Dicer. 
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Other criterion commonly used regards the conservation of the sequence 
of the micro-RNA and the stem-loop structure in various species. A “ideal”  
microRNA would have to satisfy all these criteria: only one of these criteria is 
not sufficient in order to assess that a candidate gene is a new miRNA  (Ambros 
et al., 2003c). 
 
  1.1.9. MicroRNAs and cancer 
The first evidence for miRNA involvement in human cancer came from a 
study by Calin et al. (Calin et al., 2002). Examining a recurring deletion at 
chromosome 13q14 in the search for a tumor suppressor gene involved in 
chronic lymphocytic leukemia (CLL), this study found that the smallest minimal 
common region of deletion encodes two miRNAs, mir-15a and mir-16-1. 
Analysis of their expression in CLL samples and normal CD5+ lymphocytes 
revealed that down-regulation of miR-15a and miR-16-1, which shares a 
primary transcript, is consistently associated with the deletion at chromosome 
13q14. This suggested a role of miR-15a and miR-16-1 as tumor suppressor 
genes. Subsequent investigations have confirmed the involvement of miRNAs 
in the pathogenesis of human cancer. The putative tumor suppressive role of 
miR-15a and miR-16-1 was supported by the discovery in two CLL patients of a 
germ-line point mutation that results in reduced levels of mature miR-15a and 
miR-16-1 (Calin et al., 2005), and the idea was further strengthened by the 
demonstration that miR-15a and miR-16-1 negatively regulate the anti-apoptotic 
oncogene BCL2 at a post-transcriptional level and induce apoptosis in the 
leukemic cell line MEG-01 (Cimmino et al., 2005).  
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MicroRNA deregulation can also operate in the opposite direction in 
cancer. The miR-17-92 family is the most studied example. This family includes 
fourteen homologous miRNAs, which are encoded by three gene clusters on 
chromosomes 7, 13 and X (Tanzer and Stadler, 2004). The cluster on 
chromosome 13 is amplified in human B-cell lymphomas, which leads to 
increased expression of various miRNAs. Interestingly, enforced expression of 
the miR-17-92 cluster acts together with MYC to accelerate tumor development 
in a mouse B-cell lymphoma model (He et al., 2005); it thus acts as an 
oncogene. It has been reported that transcription of this cluster is also induced 
by MYC itself; oncogenic members of the miR-17-92 cluster may therefore act 
as MYC effectors. Bi-directional relationships between oncogene activation and 
miRNA deregulation thus exist. By inhibiting oncogenes or functioning as their 
effectors, miRNAs could themselves act as tumor suppressor genes or 
oncogenes (figure 5).  
 
 
Figure 5: MicroRNA functioning as tumour soppressor (Liu et al, 2007) 
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Deregulation of miRNA expression levels emerges as the main 
mechanism that triggers their loss or gain of function in cancer cells. Genomic 
aberrations might alter miRNA expression, since miRNA up-regulation has been 
associated with genomic amplification  (O'Donnell et al., 2005), and miRNA 
down-regulation has been associated with chromosomal deletions, point 
mutations and aberrant promoter methylation (Saito et al., 2006).  
Several examples of miRNAs whose expression is deregulated in human 
cancer have been reported. Down-regulation of miR-143, miR-145 and 
members of the let-7 family has been described. The miR-143 and miR-145 
genes, which reside in a genomic cluster similar to that encoding miR- 15a/miR-
16-1, are significantly down-regulated in colon cancer tissue compared with 
colonic mucosa (Michael et al., 2003). Let-7 family regulate the RAS 
oncogenes. The 3’ UTR of the RAS mRNAs contains multiple binding sites for 
let-7 members, and forced expression of let-7 in human cancer cells reduces 
RAS protein levels (Johnson et al., 2005). Since let-7 is down-regulated in 
several human cancers, this mechanism could lead to the activation of the RAS 
pathway (Akao et al., 2006). Mir-125a and miR-125b are down-regulated in 
breast cancer (Iorio et al., 2005). These two miRNAs regulate the expression of 
the receptor tyrosine kinases ERBB2 and ERBB3 (Scott et al., 2007). Ectopic 
over-expression of miR-125a or miR-125b in SK-BR-3 cells induces impaired 
anchorage-dependent growth and reduced migration and invasion capacities, 
which is consistent with suppression of ErbB signalling.  
An example of up-regulated miRNA is miR-155, which lies in the only 
phylogenetically conserved sequence of BIC, a non protein-coding gene that 
was discovered as site of pro-viral insertions in avian leucosis-virus-induced 
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lymphomas (Tam et al., 1997). This miRNA and its primary transcript BIC are 
over-expressed in Hodgkin lymphoma, in pediatric Burkitt lymphoma and in 
diffuse large B-cell lymphoma (Eis et al., 2005). Another example of up-
regulated miRNA is miR- 21, a gene located at chromosome 17q23 in a 
chromosomal region frequently amplified in human cancer, which is up-
regulated in human breast cancer and in glioblastoma (Chan et al., 2005).  
A peculiar mechanism linking miRNA to cancer was revealed by the 
analysis of a masked chromosomal translocation t (8; 17) in a B-cell leukemia 
(Gauwerky et al., 1989), in which the mir-142 regulatory element is juxtaposed 
to the MYC proto-oncogene. Here, a miRNA regulatory element serves as a 
proto-oncogene activator. Although at present this mechanism appears to be 
unique, given the high levels and tissue-specific expression of several miRNAs 
it is a mechanism that should be further investigated in translocations identified 
in human cancer that are yet to be associated with culprit genes.  
In most cases, deregulation consistently acts in one direction, either up-
regulating or down-regulating the miRNAs, which suggests that these miRNAs 
are likely to play a crucial role in tumorigenesis. There are, however, some 
unusual situations: for example, members of the miR-181 family are up-
regulated in some cancers, such as thyroid, pancreatic and prostate carcinomas 
but down-regulated in others, such as glioblastomas and pituitary adenomas 
(Pallante et al., 2006).  
There are also examples of miRNAs deregulated in specific neoplasms: 
miR-122a, for example, a liver-specific miRNA, is down-regulated in 
hepatocellular carcinoma (Kutay et al., 2006); miR-204 and miR-211 are 
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specifically up-regulated in insulinomas (Roldo et al., 2006). Tissue-specific 
aberrant expression of miRNAs might reflect the differentiation status of the cell. 
 
1.2. Sporadic Colorectal Cancer  
1.2.1. Colorectal cancer epidemiology 
Colorectal cancer (CRC) is the commonest cancer of the alimentary tract 
in the developed world, and it was the third most commonly diagnosed form of 
cancer in the UK in 2000.  In the USA and Western Europe, Australia and New 
Zealand, the age-standardized rates of incidence of colorectal cancer among 
males are currently around 50 per 100 000, whereas in Bangladesh the rate is 
about 1 case per 100 000 (Parkin et al., 2005a). Migrants moving from regions 
of low incidence to developed countries tend to acquire the risk typical of the 
new host population within one generation. This provides strong circumstantial 
evidence to suggest that environmental factors, rather than genetic variations 
between populations, are of prime importance in the aetiology of the disease 
(Flood et al., 2000).  
The sporadic form of colorectal carcinoma emerges principally via the 
adenoma-carcinoma sequence, in which malignant tumours develop from a 
small proportion of adenomatous polyps, probably over a period of decades. 
Populations with a high prevalence of sporadic adenomas also have a high 
incidence of colorectal cancer, and patients who harbour polyps have a greater 
risk of developing colorectal carcinoma than individuals with no previous history 
of polyps. The molecular basis for the emergence of the malignant phenotype is 
also relatively well established, at least in comparison with most other human 
cancers. The morphological changes of the adenoma-carcinoma sequence are 
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associated with a progressive acquisition of abnormalities of the genome, 
including somatic mutations affecting known proto-oncogenes or tumour-
suppressor genes (Vogelstein et al., 1988). 
 For example, the so-called ‘gatekeeper’ mutation, a homozygous 
mutation of the APC gene, is thought to be amongst the earliest genetic 
changes in the adenoma-carcinoma sequence (Lamlum et al., 2000). Large 
adenomatous polyps and malignant tumours often have a mutation in the K-ras 
proto-oncogene, and mutations in the tumour suppressor gene p53 appear to 
be associated typically with the transition to a carcinoma (Gafa and Lanza, 
1998). In addition to such somatic mutations, neoplastic progression in many 
tissues is also thought to be driven partially by epigenetic modifications to the 
expression of genes regulating proliferation, apoptosis and DNA repair. The 
most thoroughly studied of these effects is gene-silencing associated with the 
aberrant methylation of CpG islands in the promoterregions of genes. This 
mechanism does not involve any alteration to the DNA sequence, but the signal 
is nevertheless transmitted through mitosis (Esteller and Herman, 2002). 
The major challenge facing those who seek to harness nutrition as a 
strategy for colorectal cancer prevention is the development of mechanistic 
hypotheses to account for interactions between diet and the disease process 
(Gunter and Leitzmann, 2006). 
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1.2.2. Risk factors 
• Obesity, physical activity and inflammation 
There is a consistent body of evidence from prospective studies to 
indicate that overweight and obesity are positively associated with risk of colon 
cancer and it have since been confirmed in prospective studies conducted in 
various parts of the world although the effects have generally been more clear-
cut in men than in women (MacInnis et al., 2006). 
Exercise was found to reduce the risk of cancer, but to have little 
influence on adenomas. High-energy intake increased the risk of cancer but not 
of adenomas, and high body-mass index (BMI) significantly increased the risk of 
large adenomas. Thus, the findings were consistent with an adverse effect of 
high body mass on the later stages of the adenoma-carcinoma sequence, 
though BMI was not shown to influence the risk of cancer (Samanic et al., 
2006). 
Abdominal visceral fat accounts for about 18% of total adipose tissue 
(Ross et al., 1992). Several recent studies have been designed to explore 
associations between the risk of colorectal cancer and high levels of abdominal 
fat. This adverse effect increased significantly with age and was stronger for 
men than for women (Moore et al., 2004).  A larger waist size was associated 
with increased risk of colon cancer in both sexes, and this effect was 
independent of BMI. Again the risk was particularly strong amongst sedentary 
subjects. The overall conclusion was that around 2 h of moderate physical 
activity per day or 1 h of more vigorous activity was associated with a risk 
reduction for colon cancer of 20–25% (Pischon et al., 2006) 
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There is a strong and growing body of evidence to suggest that obesity 
and colon cancer are causally linked by mechanisms involving chronic, 
asymptomatic inflammatory activity in the colonic mucosa. Inflammatory bowel 
disease is a well-recognized cause of colorectal carcinogenesis (Munkholm, 
2003).  
Conversely, long-term consumption of aspirin and other non-steroidal 
anti-inflammatory drugs (NSAIDs) significantly reduces the risk of colorectal 
cancer, primarily through inhibition of the pro-inflammatory enzyme 
cyclooxygenase 2 (COX-2) (Tuynman et al., 2004). Adipose tissue is a rich 
source of endocrine factors, collectively termed ‘adipokines’, which include 
leptin and adiponectin, and the cytokines, tumour necrosis factor alpha (TNF-a) 
and interleukin 6 (IL-6) (Rondinone, 2006). The adipose tissue of obese 
individuals has also been shown to recruit large numbers of macrophages that 
secrete a variety of pro-inflammatory signal molecules and cytokines (Fantuzzi, 
2005). Obesity is increasingly regarded as low-grade inflammatory condition in 
which adverse effects are exerted on a variety of target organs including, in all 
probability, the colon (John et al., 2006). 
The plausibility of a role for systemic, low-grade inflammation in the 
aetiology of sporadic colorectal cancer is supported by the observation that 
plasma C-reactive protein (CRP) levels have been shown in most studies to be 
positively correlated with the risk of disease (Otani et al., 2006). One hypothesis 
is that the pro-inflammatory milieu associated with obesity induces a mucosal 
signalling cascade involving activation of the transcription factor NF-jB and 
increased expression of inducible nitric oxide synthase (iNOS) and COX-2 
(Gunter et al., 2006). This mechanism is thought to play an important role in the 
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suppression of apoptosis, which is prerequisite for tumourigenesis (Johnson, 
2001).  
The abnormally high levels of CRP, TNF-a and IL-6 that occur in the 
plasma of obese individuals are associated with the development of insulin 
resistance, a condition characterized by impaired glucose tolerance, elevated 
plasma levels of insulin and insulin-like growth factor 1 (IGF-1), and with low 
levels of IGF binding proteins, all of which seem to be associated with 
heightened vulnerability to colon cancer in human populations (Wei et al., 
2005). 
Insulin itself causes hyperproliferation of colonic epithelial cells in vivo in 
the rat  and exposure of colorectal cancer cells to insulin, IGF-1 and TNF-a in 
vitro leads to increased rates of proliferation and impaired apoptosis, both of 
which favour tumourigenesis (Giovannucci, 2001). Furthermore, recent reports 
indicate that leptin, which is a secretory product of adipocytes and hence also 
present at abnormally high levels in the plasma of obese subjects, also 
promotes mitosis and suppresses apoptosis in colonic epithelial cells (Amemori 
et al., 2007). 
 
• Diet 
A high consumption of fat and red meat is widely regarded as a risk 
factor for colorectal cancer (Lipkin et al., 1999). Meat consumption is associated 
with increased intakes of proven rodent carcinogens including heterocyclic 
amines and polycyclic aromatic hydrocarbons derived from thermal reactions 
during cooking (Cross and Sinha, 2004). In addition, although the definition of 
processed meat tends to vary between studies and populations, most 
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processed meats contain relatively high levels of nitrite and nitrate, which 
together with protein and haem contribute to the production of mutagenic 
nitrosamines derived in the faecal stream (Bingham et al., 1996). Red meat is 
also a rich source of iron, which is itself independently associated with an 
increased risk of colorectal cancer, and which may act as an intraluminal pro-
oxidant (Lund et al., 1999). 
The fruit and vegetable intake have anticarcinogenic effects. Apart from 
studies in which all fruits and vegetables are grouped together, there have been 
a number of studies in which the roles of specific types of fruit or vegetable 
have been analysed in depth. The cruciferous vegetables (cabbages, broccoli, 
sprouts, etc.) have received a great deal of attention, mainly because they 
contain a particular group of biologically active secondary metabolites, the 
glucosinolates. There are good evidences for a consistent protective effect of 
brassica vegetables against colorectal cancer, as well as for cancer of the 
stomach and lung (van et al., 1999). This issue has become more complex, 
however, in the light of recent work demonstrating that the protective effects 
depend upon particular genetic polymorphisms of the glutathione-S-transferase 
(GST) superfamily. This group of Phase II detoxifying enzymes metabolize 
environmental chemicals including carcinogens, drugs and phytochemicals. 
Around half of the individuals in most human populations are homozygous for 
the null alleles of two genetic subtypes, GSTT1 and GSTM1, and hence cannot 
express some important components of GST activity (Lin et al., 1998). The 
GSTM1 null condition might lead to a slower rate of metabolism of glucosinolate 
breakdown products and enhance the exposure of target tissues to 
isothiocyanates. Alternatively, GST null phenotypes may be less able to 
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conjugate the breakdown products in the enterocytes and subsequently export 
them back into the lumen, thus permitting better absorption of the biologically 
active constituents (Petri et al., 2003).  
Prospective studies showing an adverse effect of meat on the risk of 
colorectal cancer have also provided evidence for a protective effect of fish 
(Norat et al., 2005). Although the evidence is still ambiguous, these findings 
have prompted interest in the possibility that a high dietary intake of n-3 
polyunsaturated fatty acids from oily fish may exert anti-carcinogenic effects on 
the colorectal mucosa, perhaps by reducing the production of pro-inflammatory 
eicosanoids and inhibiting the expression and activity of COX-2 in a manner 
analogous to aspirin and other NSAIDs (Hall et al., 2007). Both the 
epidemiology and the potential mechanisms of action of fatty acids in the 
aetiology of colorectal cancer have been recently reviewed. The epidemiological 
evidence is further confused by the observation that the protective effects of fish 
may be associated with particular genetic polymorphisms affecting the 
expression of key proteins involved in peroxisome proliferator-activated 
receptors (PPAR) signalling and COX-2 expression. For example, people 
carrying a minor polymorphism in PPARd have an increased risk of adenoma 
but not tumour, and the protective effects of fish in relation to tumour are more 
significant in those carrying a particular COX-2 polymorphismThese genes are 
associated with the control and metabolism of fatty acids and the formation of 
inflammatory eicosanoids, which supports the idea that it is the particular fatty 
acid composition of fish that is the key to the protective effects (Siezen et al., 
2006). 
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Folate, which is obtainable only from the diet or from supplements, is 
essential for normal DNA synthesis and repair because conversion of 
deoxyuridylate to thymidylate requires the reduction of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate by the enzyme 
methylenetetrahydrofolate reductase (MTHFR). A deficiency of 5,10-
methylenetetrahydrofolate leads to an imbalance in intracellular 
deoxynucleoside triphosphate pools, misincorporation of uracil into DNA and 
excess double-strand breaks (Wickramasinghe and Fida, 1994). In principle, 
low levels of 5-methyltetrahydrofolate can also reduce the availability of the 
methyl-donor S-adenosyl methionine, causing abnormal methylation of 
cytosine, both within cytosine-guanine dinucleotide sequences called CpG-
islands and associated with the promoter regions of genes, and throughout the 
non-coding DNA. Abnormal DNA methylation causes aberrant gene expression 
and genomic instability and this has been proposed as a major cause of genetic 
damage leading to cancer (Ames, 2001). Folate intake has been shown to be 
inversely related to the risk of colorectal adenomas in both case-control and 
prospective studies (Giovannucci et al., 1993).  
Vitamin D has also long been thought to be protective against colorectal 
carcinogenesis, but the situation is complicated because the vitamin D status of 
an individual depends both upon dietary intake and endogenous synthesis in 
response to sunlight. The geographical differences in risk of colorectal cancer 
might be attributable to differences in sunlight exposure. It is difficult to see how 
this hypothesis can be compatible with the very high incidences of colorectal 
cancer in Australia and New Zealand, but vitamin D has since been shown to 
suppress proliferation and promote differentiation in experimental model 
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systems and a large number of epidemiological studies provide support for the 
hypothesis that adequate vitamin D status is associated with a moderately 
reduced risk of colorectal cancer (Garland and Garland, 2006). 
 
1.3. Aim 
Given the important role of miRNA in gene regulation and in 
carcinogenesis, we hypothesized that germ-line polymorphisms in the sequence 
of miRNA or in the 3’ UTR regions targeted by miRNAs might alter the strength 
of miRNA binding, with consequences on regulation of target genes thereby 
affecting the individual’s sporadic colorectal cancer risk. To test this hypothesis, 
we made a search in dbSNP for the genes coding for all the known human 
miRNAs (from the microRNA database, miRBase, http://microrna.sanger.ac.uk), 
and we selected 8 polymorphisms of potential functional impact: 7 SNPs 
identified in 7 pre-miRNA harpin regions and one in the mature sequence of 
miR-608.  
Moreover, we evaluated 129 genes belonging to different pathways 
relevant for colorectal carcinogenesis: there are 88 genes involved in 
inflammatory processes following immune responses, 16 genes involved in the 
obesity and regulation of insulin levels, and 25 genes that, when mutated, are 
known to cause genome instability by disrupting the normal DNA repair or the 
cell cycle checkpoints. We searched for all the polymorphisms residing in the 3’ 
UTRs of the candidate genes, and assessed in silico the abilities of each SNP 
to impact the binding between miRNAs and their target sites.  
In order to verify our initial hypothesis we genotyped the 8 SNPs in 
miRNA sequences and the 15 resulting putatively functional polymorphisms in 
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697 CRC cases and 624 controls from the Czech Republic, where the incidence 
of colon cancer ranks the third highest worldwide and is the highest for rectal 
cancer (Boyle and Langman, 2000; Parkin et al., 2005b). 
The SNPs associated with the risk of sporadic colorectal cancer were 
assayed in a new independent case-control study on a three different 
populations: 377 cases and 326 controls from Barcelona, 224 cases and 449 
controls from Florence and Pisa (Italy) and 659 cases and 607 controls from 
Rhine-Neckar-Odenwald region (Germany), all already collected, promptly 
available, and already studied for other polymorphisms in previous studies 
published in international scientific journals. 
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2. MATERIALS AND METHODS 
 
2.1. Selection of genes 
Among the most acknowledged mechanisms which play a role in the 
etiology of human cancer, we focused on the genes regulating the inflammation, 
the insulin resistance, and the control of genome stability.  Thus, we selected 
the most studied genes within these categories, according to the information 
from PubMed (www.pubmed.com) and CGAP pathways 
(http://cgap.nci.nih.gov/Pathways).  
We have selected 129 genes (table 1, in appendix): there are 51 genes 
involved in inflammatory processes following immune responses, 37 
inflammatory genes related to the synthesis of prostaglandins and 
thromboxanes, 16 genes involved in the regulation of insulin levels and insulin 
resistance, and 25 genes that, when mutated, are known to cause genome 
instability by disrupting the normal DNA repair or the cell cycle checkpoints.  
For all of them, the 3’UTR regions were selected according to the UCSC 
genome browser (http://genome.ucsc.edu), and defined as transcribed 
sequences from the stop codon to the end of the last exon of each gene. 
 
2.2. Targets prediction 
 Putative miRNA binding sites within the 3’UTR of each gene were 
identified by means of specialized algorithms (e.g. Diana-MicroT, miRBase, 
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miRanda, PicTar, MicroInspector, and TargetScanS) using the default 
parameters included in the software, for each of them.  
Diana-MicroT (http://www.diana.pcbi.upenn.edu/cgi-bin/micro_t.cgi) finds 
microRNA/target duplexes that are conserved in humans and mice with the 
minimum free energy (Kiriakidou et al., 2004).  
The miRBase database (http://microrna.sanger.ac.uk/targets/v3/) is 
divided into three parts: miRBase Registry includes the microRNA gene 
nomenclature; miRBase Sequence is the primary online repository for miRNA 
sequence data and annotation; miRBase Targets is a comprehensive new 
database of predicted miRNA target genes (Griffiths-Jones et al., 2006). 
MiRAnda (http://www.microrna.org/) is an algorithm that considers the 
sequence complementarity between the mature miRNA and the target site, 
binding energy of the miRNA-target duplex, and  the evolutionary conservation 
of the target position in aligned UTRs of homologous genes (John et al., 2004).  
The MicroIspector program (http://mirna.imbb.forth.gr/microinspector/) 
generates a list of possible target sites, sorted by free energy values. 
Adaptation of temperature and free energy setting, followed by a visual 
inspection of secondary structures allows a detailed analysis. The program uses 
a “miRNA database” (in multifasta format) based on “the miRNA registry” 
(http://www.sanger.ac.uk/Software/rfam/mirna/index.shtml) (Rusinov et al., 
2005).  
TargetScan (http://genes.mit.edu/targetscan) searches the 3’UTRs for 
segments of perfect Watson-Crick complementarity to bases 2-8 of the miRNA 
(numbered from the 5' end) and assigns a free energy to miRNA: target site 
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interaction, given an internal database of miRNA and UTR sequences (Lewis et 
al., 2003).  
PicTar (http://pictar.bio.nyu.edu/) computes a maximum likelihood score 
that a given RNA sequence (3’ UTR region) is targeted by a fixed set of 
microRNA. First, PicTar sets the length of putative microRNA binding sites to 
the length of the corresponding “seed”. Second, a short 3’UTR (<300bp) cannot 
be used to reliably estimate its own background nucleotide frequencies (Krek et 
al., 2005).  
 
2.3. Selection of polymorphisms 
The SNPs residing on the miRNA binding sites were found by an 
extensive search in dbSNP (http://www.ncbi.nlm.nih.gov/SNP), using BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST/) and BLAST-SNP algorithms 
(http://www.ncbi.nlm.nih.gov/SNP/snpblastByChr.html). 
At present, it is difficult to judge which of the algorithms produces the 
most reliable and/or sensitive target predictions. The TargetScan and PicTar 
algorithms produce similar overall sets of predicted target sites; most of the 
other algorithms produce results that are significantly different from them. 
However, in order to obtain comparable measurements of the variation of ∆Gs 
between the variant and the common alleles within each polymorphic target 
site, we used only one algorithm, miRAnda, which is the most specialized for 
the calculation of ∆Gs.  
The input list of targets predicted came from all the other algorithms 
employed, even in the case when one given target was detected by only one 
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algorithm. The input list of miRNAs in miRAnda was taken from miRBase, that 
is the most updated and comprehensive database of miRNAs.  
For all the identified SNPs in the miRNA target sites, miRAnda was run 
again to assess the Gibbs binding free energy (∆G, expressed in KJ/mol) both 
for the common and the variant alleles. The difference of the free energies 
between the two alleles was computed as “variation of ∆G” (i.e. ∆∆G). Because 
in some genes the same sequence is predicted to bind several miRNAs, and 
thus SNPs in these sequences could impact the binding site of more than one 
miRNA, we used the sum of all the |∆∆G|s for each SNP (|∆∆Gtot|) as parameter 
for predicting the biological impact of the polymorphism. Although each target 
can bind only one miRNA at a time in each tissue, this approach is based on the 
basic idea that the more miRNAs are predicted to bind to a given target, the 
more likely it is that at least one of them truly binds to the target. Thus, if the 
algorithms predict that only one miRNA binds to a given target, at least in 
theory, we should consider this target less important than others predicted to 
bind many different miRNAs. Paralogue miRNAs, when reported to have a 
different sequence, are considered as different miRNAs. When summing the 
∆∆Gs, we did not account for the exactly duplicated miRNA, that are, in this 
sense, considered as unique. 
In order to give a priority list of polymorphisms having real impact on 
miRNA bindings, we ranked the values of |∆∆Gtot| and we chose (arbitrarily) the 
upper tertile of the distribution (|∆∆Gtot|≥3.10 KJ/mol) as the significant cut-off. 
In other words, when the SNP had a |∆∆Gtot|≥3.10 KJ/mol was considered 
biologically relevant, whereas for |∆∆Gtot|<3.10 KJ/mol the SNPs was 
considered biologically neutral and not included in further analyses. Moreover, 
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as second criterion for SNP selection, we excluded the SNPs having the minor 
allele frequency (MAF) lower than 0.10 (for Caucasians).  
Among 129 genes, 51 don’t have SNPs in their 3’UTR region, and 29 
don’t have SNPs in binding sites of miRNA. In the list remain 44 genes and 78 
polymorphisms in target sites, but of these only 50 SNPs are validated in the 
dbSNPs of the site NCBI, and only 32 are a MAF≥0.10. Thus, only 
polymorphisms falling in the upper tertile of |∆∆Gtot| with MAF≥0.10 were 
selected for genotyping. Finally, we obtained a list of 15 SNPs (table 2). 
Moreover, we made a search in dbSNP for the genes coding for all the 
known human miRNAs (from the microRNA database, miRBase, 
http://microrna.sanger.ac.uk), and we listed 8 polymorphisms of potential 
functional impact: 7SNPs identified in pre-miRNA harpin regions and one in the 
mature sequence of miR-608 (table 3).  
 
2.4. Genotyping 
2.4.1. Study populations 
• Czech Republic 
A hospital-based case–control study was conducted to assess gene–
environment interactions in relation to colorectal cancer risk. Cases were 
incident patients with a new diagnosis of colorectal cancer attending nine 
oncological departments (2 in Prague, 1 in Benesov, Brno, Liberec, Ples, 
Pribram, Usti nad Labem, and Zlin) all over the Czech Republic from September 
2004 to February 2006. All cases had histological confirmation of their tumor 
diagnosis. During the study period, a total of 968 cases were diagnosed with 
colorectal cancer in these hospitals. This study includes 697 (72%) patients who 
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could be interviewed and provided biological samples of sufficient quality for 
genetic analysis. The lost cases were similar to those enrolled with respect to 
age, sex, tumor location, and extent. 
Controls were selected from among patients admitted to the same 
hospital during the same period and were subjects undergoing colonoscopy for 
various gastrointestinal complaints. The reasons for undergoing the 
colonoscopy were: 1) positive Fecal Occult Blood Test (FOBT); 2) 
haemorrhoids; 3) abdominal pain of unknown origin; 4) macroscopic bleeding. 
Due to the high incidence of colorectal cancer in the Czech Republic, 
colonoscopy is largely recommended and practiced. Among 899 selected 
controls, a total of 624 (70%) were analyzed in this study. Twelve percent could 
not be interviewed because of refusal or mental or other impairment. Eighteen 
percent were interviewed but did not provide a blood sample. Controls included 
people who had benign lower abdominal pains, hemorrhoids with active 
bleeding, solitary rectal ulcer, lower GI bleeding, diverticular disease, diarrhea, 
and anemia. People with polyps, adenomas, or other diagnoses related to 
cancer or to diseases known to predispose to cancer (such as e.g. ulcerative 
colitis, inflammatory bowel disease, and Crohn’s disease) were excluded. Sex 
and broad age groups were used as stratifying criteria for frequency matching. 
Both cases and controls had to be in good mental condition, be able to see and 
hear and follow an interview and (for controls) not have diagnoses clearly 
related to cancer or chronic inflammatory diseases.  
All subjects were informed and gave written consent to participate in the 
study to allow their biological samples to be genetically analyzed, according to 
the Helsinki declaration. The design of the study was approved by the Ethical 
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Committee of the Institute of Experimental Medicine, Prague, Czech Republic 
(table 4). 
 
• Spain 
Cases are patients with a new diagnosis of CRC attending a University 
Hospital in Barcelona, Spain, between January 1996 and December 1998. All 
cases had histological confirmation of their tumour diagnosis. During the study 
period, a total of 523 cases were diagnosed with CRC in the hospital. The study 
will include those 377 (72%) who could be interviewed and who provided 
biological samples of sufficient quality for genetic analysis. Refusals were 2%, 
whereas 14% could not be interviewed because they either had died, had 
mental or some other impairment, or were released without being approached 
and could not be traced. Finally, 12% were interviewed but did not provide 
biological samples. These lost cases were similar to those included with respect 
to age, sex, tumor location, and extent.  
Controls are randomly selected among patients admitted to the same 
hospital during the same period. To avoid selection bias, the criterion for 
inclusion of controls was that the reason for the current admittance to the 
hospital should be a new disease (not previously diagnosed) for that patient. 
This criterion was used to avoid inclusion of patients with chronic diseases, who 
might be repeatedly admitted to hospital and modify their habits because of 
their disease. Sex and broad age groups were used as stratifying criteria for 
frequency matching.  
Both cases and controls had to have good mental condition, and be able 
to see and hear and follow an interview. From the daily patient admission lists, 
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candidate controls were approached and, if they met these criteria, they were 
invited to participate. Among 470 selected controls, a total of 326 (69.4%) were 
analyzed in this study. Finally, 87 (18.6%) were interviewed but did not provide 
a blood sample. From a genetic point of view, we consider the hospitalized 
controls as being representative of the general Spanish population because 
they came from very different hospital departments and included very different 
diseases. No restriction criterion was imposed regarding the diagnosis of 
controls except those previously mentioned. The distribution of controls by 
diagnostic group was as follows: internal medicine 22%; acute surgery 19%; 
urology 17%; traumatology 15%; gastroenterology 16%; and circulatory or 
respiratory 11%. Sixty controls (18%) had a diagnosis of inflammatory 
conditions that might be related to the studied polymorphisms.  
All subjects were informed and gave written consent to participate in the 
study and to allow their biological samples to be genetically analyzed, according 
to the Helsinki declaration. The study protocol was cleared by the Ethical 
Committee of the hospital (table 5).  
 
• Italy 
We used 224 cases (patients affected by colorectal cancer) and 226 
controls. These samples have been recruited from the hospitals “Careggi” of 
Florence and “Santa Chiara” of Pisa. Both cases and controls have given the 
authorization to use their samples of blood for genetic analyses; the approval 
for the study has been approved from the Ethics Committees.  
Cases have been taken consecutively from the units of surgery of the two 
hospitals. All the subjects who were not admitted to the hospital previously for 
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chronic conditions were selected. So we selected only cases of sporadic 
colorectal cancer that they manifested pathology for the first time.  
Controls were constituted from donors of blood who voluntarily have 
joined under consideration. We have excluded all the donors with inferior age to 
the 39 years, in order to approach the medium age of controls to cases. 
 
• Germans 
Colorectal cancer cases and controls were drawn from the German 
Darmkrebs: Chancen der Verhütung durch Screening (DACHS) study, a large 
population-based case-control study carried out in the Rhine-Neckar-Odenwald 
region in the southwest of Germany.  
The cases consisted of 1257 unrelated male and female subjects (33-91 
years of age; median 68) with incident invasive colorectal cancer diagnosed 
between January 2003 and March 2005. The median time between diagnosis 
and ascertainment of the cases was 14 days.  
The control group comprised 1307 unrelated male and female individuals 
(34-94 years of age; median 67). None of the controls had a personal history of 
colorectal cancer. They were randomly selected from lists of population 
registries and frequency-matched to cases by 5-year age groups, sex, and 
county of residence.  
Cases and controls were eligible if they were aged 30 years and above, 
German-speaking, and mentally and physically capable of participating in an in-
person interview of about 1 hour. The study was approved by the Ethics 
Committees of the University of Heidelberg and the State Medical Boards of 
Baden-Wuerttemberg and Rhineland-Palatinate (Germany) (table 6). 
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• Interviews 
Cases and controls were personally interviewed by trained personnel 
using a structured questionnaire to determine demographic characteristics and 
potential risk factors for colorectal cancer. For each subject age and sex were 
recorded. Study subjects provided information on their lifestyle habits, body 
mass index (BMI), diabetes, tentative occupational exposure to xenobiotics, and 
family/personal history of cancer. A detailed dietary history questionnaire 
focused on average food consumption one year before the diagnosis of 
disease. Lifelong long-term (at least six consecutive months) drug use was 
included in the questionnaire. An initial open question was followed by a list of 
20 chronic diseases that usually are treated pharmacologically and their 
treatments were recorded. No drug list was used. For each exposure, the ages 
at initial use and cessation were recorded and the cumulative duration was 
computed. Drugs were grouped using the ATC (Anatomical Therapeutic 
Chemical) classification. Other relevant risk factors explored were smoking, 
alcohol, physical activity and family history of cancer. 
 
2.4.2. Laboratory Techniques 
• TaqMan allelic discrimination 
For 19 polymorphisms, the genotyping was carried out with the 5' nuclease 
assay (TaqMan; Applied Biosystems, Foster City, CA, USA). Two TaqMan 
probes were used, one for each allele. Analysis was performed using the ABI 
PRISM® 7900HT Sequence Detection System and SDS 2.2 software (Applied 
Biosystems).  
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The reaction employed the TaqMan Universal PCR Master Mix 2X, TaqMan 
primers and probes (20X or 40X), water, and 5ng of DNA.  
 
The thermal cycle program used included: 
95°C for 10 min (to activate the AmpliTaq Gold enzy me 
Activation) 
40 cycles: 95°C for 15 sec (to denature the DNA) 
   60°C for 1 min (for the stage of annealing/exten sion) 
 
The assays ID of probes are:  
 
C_441625_10 (for CD86, rs17281995);  
C_7537839_10 (for IL12B, rs1368439); 
C_1844363_10 (for IL16, rs1131445); 
C_27465694_10 (for NOD2, rs3135500);  
C_8356120_10 (for INSR, rs1051690);  
C_8685434_10 (for ALOX15, rs916055);  
C_362670_20 (for PLA2G2A, rs11677); 
C_1311797_10 (for Raf1, rs1051208); 
C_2184704_10 (for CD4, rs3213428); 
C_15831555_10 (for INSR, rs2860171); 
C_9924799_10 (for miR-605, rs2043556) 
C_15880380_10 (for miR-492, rs2289030); 
C_2826025_10 (for miR-608, rs4919510) 
C_15946974_10 (for miR-146a, rs2910164); 
C_31185852_10 (for miR-196a-2, rs11614913); 
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The SNPs rs16870224 (PTGER4), rs11515 (CDKN2A), rs2973016 (GHR), 
rs17759989 (for miR-633) was genotyped according to an ABI assay-by-
design.  
The sequences of primers and probes for these polymorphisms are:  
 
PTGER: 5’-AGTGTCTCACTAAAGCATGAAATGTGAA-3’ (forward primer),  
5’-CCTTGTATTAACAATAAACCTTCTCACAGAGA-3’ (reverse 
primer),  
VIC-5’-CATACGATTTAAGGTATTTAA-3’ (reporter1)  
FAM-5’-CATACGATTTAAAGTATTTAA-3’ (reporter2) 
CDKN2A:  5’-CCCCGATTGAAAGAACCAGAGA-3’ (forward primer)  
5’-AGGACCTTCGGTGACTGATGAT-3’ (reverse primer) 
VIC-5’-CTAAGTTTCCGGAGGTTT-3’ (reporter1) 
FAM-5’-CTAAGTTTCCCGAGGTTT-3’ (reporter2)  
GHR:  5’-ACTCGGCCTCCCAAAGTG-3’ (forward primer) 
5’-TCCCAATGCTCTCAAGAATGATGTT-3’ (reverse primer) 
VIC-5’-TAAGCCACCGTGCCCA-3’ (reporter1) 
FAM-5’-AGCCACCATGCCCA-3’ (reporter2) 
miR-633: 5’-CTCAACCTCTCTTAGCCTCTGTTTC-3’ (forward primer) 
5’-GTGGTAGATACTATTAGCCTTCTCATTTTAGG-3’ (reverse 
primer) 
  VIC-5’-TTTATTGCGGTAGATACTAT-3’ (reporter1) 
  FAM-5’-TTATTGCGGTAGGTACTAT-3’ (reporter2) 
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• Oligonucleotide allele specific PCR (ASO-PCR) 
 
For 2 polymorphisms (rs360727, IL18 and rs3746444, miR-499) 
genotyping was carried out with the oligonucleotide allelic specific PCR. 
In this technique three oligonucleotide primers are used: a primer forward 
(or reverse, F1 or R1) with a sequence complementary to the interest DNA 
fragment that finishes at the level of the allele wild-type of the 
polymorphism, an other primer forward (or reverse, F2 or R2) that, instead, 
it recognizes the variant base present on the polymorphic site, and 
common primer reverse (or forward, R or F).  
The sequences of primers for these polymorphisms are: 
 
IL18 (rs360727, G/A):  R1: 5’-CGGCTCACCACAACCTCC-3’  
R2: 5’-CGGCTCACCACAACCTCT-3’ 
F: 5’-TGTTCACTGTTCAAAACGAAGAC-3’ 
SIZE PCR: 273bp 
 
miR-499 (rs3746444, T/C): R1: 5’-GTTTAACTCCTCTCCACGTGAACA-3’  
R2: 5’-GTTTAACTCCTCTCCACGTGAACG-3’ 
F:  5’-CCAGAATTGGATGCCGCAGT-3’ 
 
SIZE PCR: 267 bp  
 
We prepared two different mixes, since in one the primers are 
added the primers F and R1 in order to amplify the region with the allele 
wild-type, in the other are added the primers F and R2 in order to amplify 
the region with the variant allele. 
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For the SNP within the gene IL18 the protocol is: 
 
MIX1 (for the wild-type allele)       MIX2 (for the variant allele) 
Primers (10 µM): 0.5 µl F + 0.5 µl R1
  
    Primers (10 µM): 0.5 µl F + 0.5 µl R2 
Buffer BD (10X): 2 µl        Buffer BD (10X): 2 µl 
MgCl2 (25mM): 1.2 µl                        MgCl2 (25mM): 1.2 µl       
dNTPs (2mM): 2 µl         dNTPs (2mM): 2 µl 
H2O: 10,6 µl         H2O: 10,6 µl 
Hotfire® Taq polimerasi: 0,2 µl          Hotfire® Taq polimerasi: 0,2 µl   
 
DNA: 3 µl  (30 ng/ µl)           DNA: 3 µl  (30 ng/ µl)    
 
 
 
For the SNP within miR-499 the protocol is: 
 
MIX1 (for the wild-type allele)       MIX2 (for the variant allele) 
Primers (10 µM): 1 µl F + 1 µl R1
         
Primers (10 µM): 1 µl F + 1 µl R2 
Buffer BD (10X): 2 µl        Buffer BD (10X): 2 µl 
MgCl2 (25mM): 0,6 µl                        MgCl2 (25mM): 0,6 µl       
dNTPs (2mM): 2 µl         dNTPs (2mM): 2 µl 
H2O: 10,2 µl         H2O: 10,2 µl 
Hotfire® Taq polimerasi: 0,2 µl          Hotfire® Taq polimerasi: 0,2 µl   
 
DNA: 3 µl  (30 ng/ µl)           DNA: 3 µl  (30 ng/ µl)    
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The thermal cycle program used for both SNPs included: 
 
  95 °C for 8 min (to active the Hotfire® Taq polim erasi) 
20 cycles 95°C for 30 sec (to denature the DNA) 
  68°C for 30 sec, -1°C/cycles (hybridization of pr imers) 
  72°C for 1 min and 30 sec (the stage of extension ) 
20 cycles 95°C for 30 sec (to denature the DNA) 
  51°C for 30 sec (hybridization of primers) 
  72°C for 1 min and 30 sec (the stage of extension ) 
    
72°C for 10 min (to complete the synthesis) 
   4°C forever 
 
The visualization of the PCR products was carried out through 
electrophoresis in 2% agarose gel, obtained through the polymerization of 
5 g of agar in 250 ml TBE 0,5X (TRIS borat-EDTA buffer) , with the 
addition of 8 µl of Ethidium Bromide (10mg/ml), at 180V for 20 minutes.  
 
• Fragment Analysis 
For 2 polymorphisms (rs3783553, IL1A and rs5745925, miR-631) 
genotyping was carried out with the DNA Fragment Analysis. In this methodical 
the regions containing the SNPs are amplified by duplex PCR using 
fluorescently labeled reverse and unlabeled forward primers. The PCR 
amplicons are separated by size using capillar electrophoresis; then the dye 
labeled products are identified by fluorescence detection. Analysis was 
performed using the ABI PRISM® 3100 Genetic Analyzer and the 
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GeneMapper®   Version 3.7 Software. Before the use the DNA samples were 
put in plates from 96 wells. 
The sequences of primers for the polymorphisms are: 
 
IL1A 
(rs3783553, TTCA/-): F: 5’-CTCTGAGTGTGACCAGGCATC-3’ 
R: Fam- 5’-GAACCTAGAAGAAACATTGATTACA- 3’ 
 
For the wild type allele the size PCR is: 363 bp 
For the wild type variant allele the size PCR is: 359 bp 
 
MiR-631 
(rs5745925, CT/-): F: 5’-GCTGAGGTCACATCACCAGA -3’  
R: Fam-5’-TCTCTGACCCGTAGCCTTTG -3’ 
 
For the wild type allele the size PCR is: 176 bp 
For the wild type variant allele the size PCR is: 174 bp 
 
The protocol of duplex PCR for plate is: 
 
 
Primers(10 µM): 100µl F(IL1A)+ 100µl R(IL1A)+100µl F(miR-631)+100µl R(miR-631) 
Buffer BD (10X): 200 µl 
MgCl2 (25mM): 240 µl                      
dNTPs (2mM): 200 µl      
H2O: 630 µl      
Hotfire® Taq polimerasi: 30 µl       
DNA: 3 µl (30 ng/ µl)    
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The thermal cycle program used included: 
 
35 cycles 95°C for 1 min (to denature the DNA) 
   58°C for 30 sec (hybridization of primers) 
   72°C for 10 min (the stage of extension) 
 
   72°C for 10 min (to complete the synthesis) 
    4°C forever 
After the amplification, to 1 µl of PCR product for everyone samples were added 
10 µl of Rox500 and HiDi Formamide (dilution 1:40). 
 
2. 4. 3. Statistical Analysis 
Each polymorphism was tested to ensure the fitting with Hardy–Weinberg 
equilibrium with alpha-threshold of 0.05. We used a multivariate logistic 
regression analysis to examine associations between these polymorphisms and 
CRC risk by estimating the odd ratios (ORs) and 95% confidence intervals 
(CIs), adjusted for sex and age (as linear variable) as covariates. Genotypes 
have been divided into three groups: major allele homozygous (also defined as 
+/+), heterozygous (+/-), and homozygous variant (-/-). This analysis had been 
done using a co-dominant model: ORs and 95% CI were calculated for each 
genotype compared to the group +/+. Test for linear trend of ORs were 
calculated using the categorized variable as quantitative, after assigning a linear 
score to each ordered category. When associations were detected, also the 
recessive (homozygotes variant vs heterozygotes+homozygotes common 
allele) and dominant (homozygotes variant+heterozygotes vs homozygotes 
common allele) models were evaluated. All statistical analyses were conducted 
using STATA software version 8.0 (Stata Corp. LP, College Station, TX). 
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3. RESULTS 
 
Among the 129 starting candidate genes, 56 did not present any SNP in 
their 3’UTR regions and 29 genes did not show SNPs in miRNA target 
sequences. The remaining 44 genes showed 78 SNPs in the predicted miRNA 
binding sites. However, among them, only 15 SNPs were positive for both the 
selection criteria (|∆∆Gtot|≥ 3.10 KJ/mol and MAF>0.10) and were further 
investigated in the case-control study.  
Table 2 shows the nucleotide variation, the predicted binding miRNAs, 
variation of ∆G (|∆∆G|) for each miRNA, and the overall |∆∆Gtot| for the 15 
selected SNPs. These SNPs were in the 3’ UTR of CD4, CD86 and NOD2 
(receptors involved in the immune response), IL-1A, IL-18, IL16 and IL12B 
(cytokines), ALOX15, PLA2G2A, and PTGER4 (bio-synthesis of prostaglandins 
and thromboxanes), INSR and GHR (obesity and insulin resistance), and RAF-1 
and CDKN2A (early and late stages of the tumour). To this list we added 7 
SNPs in the sequence of pre-miRNA (miR-146a, miR-499, miR-605, miR-492, 
miR-631, miR-633, miR-196) and one in the mature sequence of miR-608. The 
variations and the frequencies of these polymorphisms are in appendix (table 
3). 
We tested the genotypes for Hardy-Weinberg equilibrium, using p=0.05 
as significance threshold and all 23 SNPs were in equilibrium in controls. Table 
7 shows the statistical analyses, for the co-dominant model only, for the Czech 
Republic population. Both the heterozygotes and homozygotes for the variant 
allele rs17281995 within CD86 were associated with an increased risk of CRC 
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(OR=1.38; 95%CI=1.05-1.83 and OR= 2.74; 95%CI= 1.24-6.04, respectively). 
Moreover, the homozygotes for the variant allele rs1051690 within INSR 
showed an OR of 1.94 with a 95% Confidence Interval of 1.03-3.66.  It is 
important to note that the association found for CD86 in the dominant model, 
with an OR of 1.48 (95%CI= 1.13-1.94; P= 0.015) was also very close to this 
tight limit of significance. Stratifying for the site of cancer, the increased risk for 
CD86 was observed both for the colon and rectum; however, it was more 
evident in the rectum (OR=1.5; 95%CI 1.05-2.15; p=0.028, dominant model).  
For these two polymorphisms we used a multivariate logistic regression 
analysis with the other populations: in table 8 there are the results for the co-
dominant model for the Spain population. For the SNP in CD86 the association 
for homozygotes for the variant allele was confermed, but the 95% Confidence 
Interval was too wide (OR=1.34; 95%CI 0.51-3.48). The heterozygotes was no 
more associated with an increased risk of CRC (OR=0.97; 95%CI 0.66 1.42).  
Nevertheless the homozygotes for the variant allele in INSR showed an OR of 
3.20 with a 95% Confidence Interval of 1.05-9.78, in agreement with the 
previus results on the Czech Republic population.  With the recessive model 
the association was confermed for both SNPs (OR=1.35; 95%CI=0.55-3.49 and 
OR= 3.20; 95%CI= 1.05-9.75, respectively). Also in this case the 95% 
Confidence Interval was too wide for CD86.  
Table 9 show the co-dominant model for CD86 and INSR in the Italian 
population. The odd ration for the homozygotes for the variant allele 
rs17281995 within CD86 was 0.30 and 95%CI=0.4-2.32, whereas for the 
heterozygotes the OR was 1.18 with a 95%CI= 0.68-2.02. The homozygotes 
whitin INSR show an OR of 1.74 (95%CI= 0.29-10.48).  
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These discordant results with the first population could be due to a 
reduced number of samples used for the study. 
In table 10 there are the results for the German population. For the 
homozygotes for the variant allele of CD86 the OR was 1.01 (95%CI= 0.60-
1.69), while for the heterozygotes the OR was 1.15 (95%CI= 0.95-1.37). The 
heterozygotes for INSR show a OR of 1.1 (95%CI= 0.90-1.30). 
 Finally, we made a general multivariate logistic regression analysis using 
all the samples (Czech, Spanish, Italian, and German) (table 11). We confirmed 
the association between risk of CRC and the polymorphisms in CD86 
(rs17281995) (OR=1.40, 95%CI= 1.02-2.01 and OR= 1.15, 95%CI=1.01-1.31, 
respectively for the homozygotes and the heterozygotes, co-dominat model) 
and INSR (rs1051690) (OR=1.41, 95%CI= 1.01-1.94, for the heterozygotes, co-
dominant model).  
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4. DISCUSSION 
 
In the present study two polymorphisms (rs17281995 in CD86 and 
rs1051690 in INSR) were found associated with an increased risk of CRC. We 
were aware that there could be a potential bias in this study because controls 
were selected among people undergoing colonscopy. However, in terms of diet, 
socio-economic status, ethnic and familial origins, and all the variables collected 
with in questionnaires, there is no evidence that the controls are not 
representative of the general population. Five different miRNAs bind to a target 
site that contains the same polymorphism within CD86: miR-337, miR-582, miR-
200a*, miR-184, and miR-212 (table 2). When C substitutes G, miR-337, miR-
582, and miR-200a* are predicted to bind less tightly to the CD86 3’UTR. In 
contrast, miR-184 and miR-212 increase their binding affinity. Among all the 
SNPs analyzed, this is the only one that impacts the binding site of 5 different 
miRNAs at the same time. In other words, the SNP that produces the largest 
predicted effect it is also the most strongly associated with risk in the present 
case-control association study. Furthermore, it should be considered that part of 
the selected miRNA target sites could have been the result of erroneous 
prediction by the algorithms (limited experimental information is available for 
most of the selected miRNAs, according to the latest update of Tarbase 4.0; 
http://www.diana.pcbi.upenn.edu/tarbase.html).  
It should be stressed that miR-582 was shown to be present in normal 
colon tissues, and its expression appeared to be reduced in CRC following 
measurements done with quantitative real-time PCR (Cummins et al., 2006). 
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We could speculate that this finding seems in agreement with the fact that the 
SNP predicted to cause a reduced binding of miR-582 to its target is associated 
with increased risks of CRC. Taken together, all these facts encourage further 
investigation, by replicating the results in other populations and by making in 
vitro experiments in the biological activity of these polymorphisms.  
CD86, with CD80, is a co-stimulatory ligand expressed on the surface of 
the antigen presenting cells (dendritic cells, macrophages, and B cells), in the 
immune system (Orabona et al., 2004). Binding of these molecules to the T cell 
co-stimulatory receptors, CD28 and CTLA-4, is essential for the activation and 
regulation of T-cell immunity (Bhatia et al., 2006). Functionally, the binding of 
CD28 with CD80 and CD86 ligands delivers a positive signal to T-cells that 
culminates in T-cell proliferation, cytokine production, and prevents induction of 
T-cell tolerance (Linsley et al., 1991). In contrast, the interaction of CTLA-4 with 
CD80/CD86 results in negative signaling leading to attenuation of T-cell 
activation. Such processes are essential for the regulation of a T-cell response 
and maintaining T-cell homeostasis (Tivol et al., 1995). CD80 and CD86 have 
been shown to modulate also the Th1/Th2 T-cell differentiation. While CD80 
preferentially favours Th1 type T-cell differentiation, CD86 augments IL-4 
production and overall Th2 type T-cell responses (mostly producing anti-
inflammatory cytokines) (Suvas et al., 2002). Normal colonic tissue expresses 
CD80 and CD86 only sporadically, whereas in the pathogenesis of Crohn’s and 
inflammatory bowel diseases, a sharp increase is observed paralleling the 
impaired and/or excessive activation of mucosal macrophages and T-
lymphocytes (Vuckovic et al., 2001). It should be considered that even a normal 
colonic mucosa undergoes a continuous state of sub-
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to the normal bacterial activity present within its lumen (Kelly and Conway, 
2005). Thus, our results support the hypothesis that the regulation of the 
immune response and its consequent level of local inflammatory micro-
environment could play an important role for the modulation of the individual 
risk. CD86 is likely one of the key molecules involved in these processes. If we 
assume the role of miR-582 for CD86, one could speculate that the rare variant 
of rs17281995 is linked to increased levels of CD86, thereby favoring an 
inflammatory micro-environment predisposing to CRC. 
Although less strongly associated with the risk of CRC, it is worth to note 
that also the variation G/A within the 3’ UTR of INSR has a predicted strong 
impact in the biology of the miRNA target, as it can be observed by the fifth 
strongest |∆∆Gtot| (11.25 KJ/mol, see table 2). It is important to stress that this 
value is due largely by the predicted alteration with miR-612 (7.41 KJ/mol), the 
second strongest individual |∆∆G| observed in this study.  
The levels of glucose and insulin increase after each meal. Following 
binding of insulin to the extra-cellular portion of the insulin receptors (IRs), a 
second messenger system diverges into two separate pathways that regulate 
distinct biological effects: the PI3K pathway or the MAP kinase pathway 
(Taniguchi et al., 2006). In insulin resistance, the ability of insulin to initiate 
these phosphorylation cascades is diminished (Pirola et al., 2004). 
Epidemiologic studies indicates that the insulin resistance, elevated fasting 
plasma insulin, glucose and free fatty acids, glucose intolerance, increased 
body mass index, and visceral adiposity, are all associated with adenomas, a 
precursor lesion for CRC (Keku et al., 2005). Several mechanisms exist 
whereby insulin signaling can be modulated at the level of the INSR. Generally, 
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these processes involve either the modification of INSR contained in the cells at 
the level of transcription or protein degradation, or by modification of the 
enzymatic activity of individual INSR (Youngren, 2007). Puig and Tijan (Puig 
and Tjian, 2005) have demonstrated that the FOXO1 transcription factor 
mediates a down-regulation of INSR transcription in response to insulin 
stimulation of IR signaling (Okabayashi et al., 1989b). Insulin also reduces the 
effective concentration of cellular IR by increasing internalization and 
degradation of the protein as well (Okabayashi et al., 1989a). Activation of this 
system produces a down-regulation of multiple components of the insulin 
signaling system (Rome et al., 2004). The SNP rs1051690 3’UTR could affect 
INSR regulation by a miRNA mediated mechanism. To confirm that the 
regulation of transcription or translation of INSR is a important mechanism 
implicated in colorectal risk, there is a study of Pechlivanis and your group. 
They found a significant association between a INSR (A-603G, rs1864010) 
genotypes and risk ofCRC (global X2=6.15, P=0.046) (Pechlivanis et al., 2007). 
In the INSR gene, the region 1800 bp upstream of the translation start site 
contains many regulatory elements which have been reported to be required for 
proper expression of INSR and appropriate insulin signaling and action (Foti et 
al., 2003). The removal or mutational inactivation of the four Sp1 elements 
present between -618 and -593 bp has been shown to reduce promoter activity 
of the gene by about 90% (Yoshizato et al., 2001). The A-603G polymorphism 
lies within the consensus sequence for Sp1 binding and has been shown to 
affect Sp1 binding. However, a later study has not observed any effect of this 
SNP on the promoter activity (Haruta et al., 1995). Interestingly, in the G allele 
carrier status was associated with a significantly decreased risk for CRC. In 
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consistence with these results, the A allele has been suggested to be a risk 
factor for insulin resistance (Kadowaki et al., 1990). 
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5. CONCLUSIONS 
 
In conclusion, we have analyzed 129 CRC-related genes and selected with 
in silico methods 15 SNPs predicted to have an impact on miRNA binding. To 
this list we added 7 SNPs in pre-miRNA sequences and 1 in a mature sequence 
of miR-608. Two of them were associated with CRC risk. This study provides 
evidence that these SNPs in microRNA binding sites may be important for 
cancer risk and supports future work to validate the results in other well 
characterized populations as well as to explore the biological significance of 
these particular SNPs. Our work is the first showing an association between 
cancer risk and polymorphic miRNA binding sites. These results show also that 
a careful a priori selection of candidate SNPs could increase the signal-to-noise 
ratio in case-control association studies. The proposed approach could ease the 
identification of functionally relevant polymorphisms involved in carcinogenesis 
to be further analysed by appropriate (but time consuming) experiments of 
molecular biology. 
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6. FUTURE PROSPECTIVES 
 
For the future we will follow two lines of research. First, we will continue the 
association study on a new set of genes. In particular, we will apply the 
approach to 144 candidate cancer genes selected by Vogelstein. In this study, 
20857 transcripts were analysed from 18191 human genes, including the great 
majority of those that encode proteins. The genes were sequenced in 11 
colorectal cancers. Any gene that was mutated in the tumour but no in normal 
tissue from the same patient was analysed in 24 additional tumors. Selected 
genes were further analyzed in another 96 colorectal cancer to better define 
their mutation frequency (Wood et al., 2007).  
Second, we will study, with the use of gene reporters, the SNPs in CD86 
and INSR. We will clone the 3′-UTR of the target gene downstream of the 
luciferase (with the wild type allele and with the variant allele in the polymorphic 
site) and will transfect these recombinant plasmids and a miRNA of interest into 
a host cell. Thus, Lucifer's activity will be measured.  
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APPENDIX 
Table1. Starting list of candidate genes evaluated for the presence of 
polymorphic miRNA target sites. 
 
Gene 
symbol 
Gene name Gene 
symbol 
Gene name 
ACDC adiponectin and collagen domain containing  INS insulin  
ALOX12 arachidonate 12-lipoxygenase INSR insulin receptor 
ALOX12B arachidonate 12-lipoxygenase, 12R type IRS1 insulin receptor substrate 1 
ALOX15 arachidonate 15-lipoxygenase IRS2 insulin receptor substrate 2 
ALOX15B arachidonate 15-lipoxygenase, second type JAK2 Janus kinase 2 
ALOX5 arachidonate 5-lipoxygenase KRAS v-Ki-ras2 Kirsten rat sarc. viral onc. homolog  
APC Adenomatosis polyposis coli LEP leptin 
AXIN1 Axin LEPR leptin receptor  
BTRC beta-transducin repeat-containing protein MCC mutated in colorectal cancers  
CD28 CD28 antigen MDM2 Mdm2, transf. 3T3 cell double minute 2 
CD3D CD3D antigen, delta polypeptide MLH1 mutL hom. 1, colon canc, nonpolyp. type 2 
CD3E CD3E antigen, epsilon polypeptide MSH2 mutS hom. 2, colon canc, nonpolyp. type 1 
CD3G CD3G antigen, gamma polypeptide MSH6 mutS homolog 6 (E. coli)  
CD3Z CD3Z antigen, zeta polypeptide NFkB1 Nucl. fact. K-light polyp. enhancer B-cells 
CD4 CD4 antigen (p55)  NOD1 Nucleotide-binding oligomer. domain1 
CD80 CD80 antigen NOD2 Nucleotide-binding oligomer. domain2 
CD86 CD86 antigen NR1H2 Nucl. recept. subfam. 1, group H, member 2 
CDKN2A p16(INK4); p14(ARF) NR1H3 Nucl. recept. subfam. 1, group H, member 3 
CTBP1 c-terminal-binding protein 1 NRAS neuroblast. RAS viral (v-ras) onc. homolog  
CTLA4 Cytotoxic T-lymph.-associated protein 4  PGDS prostaglandin D2 synthase 
CTNNB1 Catenin (cadherin-associated protein), beta PI3K phosphoinositide-3-kinase, gamma pol. 
DCC deleted in colorectal carcinoma  PLA2G10 phospholipase A2, group X 
DVL2 Dishevelled, dsh homolog 2 (Drosophila) PLA2G2A phospholipase A2, group IIA 
ELOVL6 long chain fatty acyl elongase PLA2G4A phospholipase A2, group IVA 
FABP5 fatty acid binding protein 5 PLA2G6 phospholipase A2, group VI 
FADS1 fatty acid desaturase 1 PMS1 PMS1 postmeiotic segregation increased 1 
FADS2 fatty acid desaturase 2 PMS2 PMS2 postmeiotic segregation increased 2 
FADS3 fatty acid desaturase 3 PPARD peroxisome prolif. activated receptor, delta 
FZD1 Frizzled homolog 1 (Drosophila) PPARG peroxisome prolif. activated receptor, gamma 
GH growth hormone  PPARGC1A PPARg co-activator 1, alpha 
GHR growth hormone receptor  PRKCB1 Protein kinase C, beta 1 
GMCSF Colony stimulating factor 2 PTGDS prostaglandin D2 synthase, brain 
AES GROUCHO/amino-terminal enhancer of split PTGER1 prostaglandin E receptor 1, EP1 
GSK3B Glycogen synthase kinase 3 beta  PTGER2 prostaglandin E receptor 2, EP2 
HNF4A hepatocyte nuclear factor 4, alpha PTGER3 prostaglandin E receptor 3, EP3 
HRAS v-Ha-ras Harvey rat sarc. viral onc. homolog  PTGER4 prostaglandin E receptor 4, EP4 
IFNG Interferon gamma PTGES prostaglandin E synthase 
IGF1 Somatomedin C  PTGES2 prostaglandin E synthase 2 
IGF1R insulin-like growth factor 1 receptor PTGIS prostaglandin I2 synthase 
IGF2 Somatomedin A  PTGS1 Cyclooxygenase-1 
IGFALS IGF, acid labile subunit PTGS2 Cyclooxygenase-2 
IGFBP1 insulin-like growth factor binding prot. 1 RAF1 v-raf-1 murine leuk viral onc. homolog 1 
IGFBP3 insulin-like growth factor binding prot. 3 RARA retinoic acid receptor, alpha 
IL10 Interleukin 10 RXRB retinoic X receptor, beta 
IL12A Interleukin 12 SCD steoryl-CoA desaturase 
IL12B Interleukin 12B SMAD4 mothers against decapentaplegic homolog 4 
IL12RB2 Interleukin 12 receptor, beta 2 SREBF1 sterol reg. element binding transc. fact. 1 
IL15 Interleukin 15 STAT4 Signal transducer/activator of transcr. 4  
IL16 Interleukin 16 TBXAS1 thromboxane A synthase 1 
IL18 Interleukin 18 TCRA T cell receptor alpha locus  
IL1A Interleukin 1, alpha TCRB T cell receptor beta locus  
IL1B Interleukin 1, beta TGFB1 transforming growth factor beta 
IL1R1 interleukin 1 receptor, type I  TLR1 Toll-like receptor-1 
IL1R2 interleukin 1 receptor, type II  TLR2 Toll-like receptor-2 
IL2 Interleukin 2 TLR3 Toll-like receptor-3 
IL23 Interleukin 23 TLR4 Toll-like receptor-4 
IL2RA Interleukin 2 receptor, alpha   TLR5 Toll-like receptor-5 
IL2RB Interleukin 2 receptor, beta TLR6 Toll-like receptor-6 
IL2RG Interleukin 2 receptor, gamma TLR7 Toll-like receptor-7 
IL3 Interleukin 3 TLR8 Toll-like receptor-8 
IL4 Interleukin 4 TLR9 Toll-like receptor-9 
IL5 Interleukin 5 TNFA Tumor necrosis factor alpha 
IL6 Interleukin 6 TP53 tumor protein p53 (Li-Fraumeni syndrome)  
IL7 Interleukin 7 WNT1 Wingless-type MMTV integration site fam. 1 
IL8 Interleukin 8   
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Table2. Candidate SNPs in miRNA target sequences, ranked by ∆∆G, expected 
to have a high impact on the ∆G (|∆∆GTOT|>3.10 KJ/mol) and with a frequency 
higher than 0.10 in Caucasians. 
 
|∆∆G| |∆∆GTOT| 
Gene dbSNP ID Variation Frequency miRNA KJ/mol KJ/mol 
ALOX15 rs916055 T/C 0,27 miR-588 4,29 7,50 
  
      miR-183 3,21   
CD4 rs3213428 A/G 0,21 miR-518 3,10 3,10 
CD86 rs17281995 G/C 0,11 miR-337 5,76 20,81 
  
   miR-184 4,51   
  
   miR-200a* 4,32   
  
   miR-212 2,20   
  
      miR-582 4,02   
CDKN2A rs11515 C/G 0,18 miR-601 5,27 5,27 
GHR rs2973016 G/A 0,11 miR-608 2,85 8,52 
  
      miR-196b 5,67   
IL12B rs1368439 A/C 0,32 miR-513 6,50 15,10 
  
   miR-210 4,20   
  
   miR-27a 2,20   
  
      miR-27b 2,20   
IL16 rs1131445 T/C 0,31 miR-135a 3,93 9,53 
  
   miR-135b 3,93   
  
   
miR-143 0,66 
  
  
   
miR-18 0,51 
  
  
      
miR-18a 0,50 
  
IL18 rs360727 G/A 0,17 miR-197 6,99 11,39 
  
      miR-361 4,40   
IL1A rs3783553 TTCA/- 0,41 miR-180 19,91 58,35 
  
   miR-422b 0,52   
  
   miR-206 13,85   
  
      miR-608 24,07   
INSR rs1051690 G/A 0,15 miR-612 7,41 11,25 
  
      miR-618 3,84   
INSR rs2860171 C/T 0,16 miR-608 7,12 15,04 
  
      miR-526a 7,92   
NOD2 rs3135500 G/A 0,33 miR-158 6,87 14,69 
  
   miR-215 6,87   
  
   
miR-98 0,64 
  
  
      
miR-573 0,31 
  
PLA2G2A rs11677 C/T 0,11 miR-187 7,90 14,09 
  
   
miR-638 2,81 
  
  
   
miR-154 1,81 
  
  
   
miR-453 1,37 
  
        
miR-296 0,20 
  
PTGER4 rs16870224 G/A 0,10 miR-9 4,40 10,30 
  
      miR-30a-3p 3,10   
RAF1 rs1051208 C/T 0,22 miR-213 3,98 5,28 
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Table3. Candidate SNPs in sequences encoding miRNAs 
 
 
 
 
 
 
 
 
Table4. Characteristics of cases and control subjects: Czech Republic 
population.  
 
  
Cases Controls 
  
(n=697) (n=624) 
    
Males/Females (%) 
 57.2/48.2 53.6/46.4 
Age Average 61.1 yrs 56.0 yrs 
 Lower Quartile 55 yrs 47 yrs 
 Upper quartile 69 yrs 66 yrs 
Rectal cancer (%) 
 38.4  
Colon cancer (%) 
 61.7  
Smoking Non smokers (%) 53.6 52.8 
 Ex-smokers (%) 32.3 26.4 
 Smokers (%) 14.1 20.9 
Positive family history of colorectal 
cancer 
no (%) 82.0 84.3 
 yes (%) 18.0 15.7 
Percentage of strictly vegetarian (%) 
 10.9 7.8 
Alcohol consumption no (%) 47.3 40.2 
 yes (%) 52.7 59.8 
Mean gr of alcohol/day 
 23.1 22.9 
Living Place City (%) 57.2 56.2 
 Suburbs (%) 15.5 21.2 
 Country (%) 27.3 22.7 
Education Basic (%) 33.5 25.4 
 High School (%) 51.6 54.8 
 University (%) 14.9 19.8 
Mean BMI (Kg/m2)±SD  26.7±4.3 26.7±4.5 
Distribution of the populations according 
to BMI: <18.5 Kg/m
2
 (%) 1.56 0.73 
 
18.5-24.9 Kg/m2 
(%) 37.0 37.9 
 
25-29.9 Kg/m2 
(%) 42.5 41.5 
 
30-34.9 Kg/m2 
(%) 15.1 15.3 
 
≥35 Kg/m2 (%) 3.80 4.61 
  
Gene dbSNP Variation Frequency 
miR-608 rs4919510 C/G 0.167 
miR-146a rs2910164 G/C 0.239 
miR-499 rs3746444 A/G 0.174 
miR-605 rs2043556 U/C 0.139 
miR-492 rs2289030 C/G 0.082 
miR-631 rs5745925 CT/- 0.065 
miR-633 rs17759989 A/G 0.042 
miR-196a-2 rs11614913 C/T 0.440 
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Table5. Characteristics of cases and control subjects: Spain population.  
 
  
Cases Controls 
  
(n=337) (n=326) 
    
Males/Females (%) 
 59,7/40,3 53.1/46.9 
Age <58 21,7 26,4 
 58-67 24,7 26,7 
 68-75 29,2 20,2 
 >75 24,4 26,7 
Rectal cancer (%) 
 36,8  
Colon cancer (%) 
 63,2  
Mutation TP53 77,0  
 
ras 36,7  
Family history of colorectal 
cancer 
 11,7 3,8 
Smoking Non smokers (%) 53,2 55,9 
 
Ex-smokers 
(%) 31,6 26,1 
 Smokers (%) 15,2 18,0 
    
Alcohol drinker (> 10g/week) never 34,6 43,3 
 <40 years 31,7 30,5 
 >40 years 35,3 25,0 
Caloric intake <1688 29,2 37,9 
 1688-2246 34,4 31,9 
 ≥2246 36,3 30,2 
Use of drugs 
(weekly during >6 months) 
Acetylsalicylic 
acid 16,1 17,0 
 
Other NSAIDs 5,8 14,5 
 
Paracetamol 10,5 17,4 
 
Antiulcer 16,9 13,6 
 
Laxatives 17,2 14,5 
BMI (at diagnosis) >25 44,5 38,5 
 
25-29 41,5 39,4 
 
≥30 14,0 22,1 
BMI (10 years befor diagnosis) >25 36,2 37,5 
 
25-29 43,8 43,0 
 
≥30 20,0 19,5 
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Table6. Characteristics of cases and control subjects: German population  
 
  
Cases Controls 
  
(n=659) (n=607) 
  % % 
    
Males/Females (%) 
 58,4/41,6 56.8/43.2 
Age 33-54 9,9 11,2 
 55-64 25,3 28,8 
 65-74 36,4 37,9 
 75-94 28,4 22,1 
Rectal cancer (%) 
 37,5  
Colon cancer (%) 
 62,2  
First-degree family history of 
colorectal cancer No 79,2 79,9 
 
Yes 12,9 11,2 
 
Unknown 7,6 8,9 
UICC stage at diagnosis I 21,7  
 
II 32,5  
 
III 28,1  
 
IV 17,3  
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Table7a. Logistic regression analysis for the selected SNPs in the miRNA target sequences. Only the co-dominant model is shown. 
 
      
CASESA 
    
CONTROLSA 
  
OR HOMOZYGOTES 
  
OR HETEROZIGOTES 
Genes SNP Ref. WT/WT WT/MUT MUT/MUT WT/WT WT/MUT MUT/MUT ORB LOW 95% UP 95%  ORB LOW 95% UP 95%  
IL1A rs3783553  293  173 19 333 209  16 0,761 0,378 1,534 1,087 0,836 1,411 
IL12B rs1368439 446 183 21 417 174 14 1,402 0,692 2,840 0,965 0,749 1,243 
NOD2 rs3135500 234 294 114 228 282 85 1,265 0,898 1,783 0,977 0,759 1,256 
PLA2G2A rs11677 521 118 10 468 114 8 1,201 0,451 3,196 0,917 0,684 1,230 
IL18 rs360727 651 21 2 581 29 1 1,880 0,160 22,220 0,740 0,410 1,330 
CD86 rs17281995 459 156 24 464 117 9 2,740 1,243 6,041 1,384 1,047 1,829 
PTGER4 rs16870224 505 127 10 464 122 4 2,624 0,784 8,781 0,978 0,735 1,303 
IL16 rs1131445 298 276 63 259 257 58 0,951 0,636 1,423 0,957 0,749 1,221 
ALOX15 rs916055 270 307 67 231 308 57 1,050 0,701 1,574 0,832 0,653 1,061 
RAF1 rs1051208 474 158 12 426 165 13 0,720 0,318 1,628 0,878 0,676 1,140 
CDKN2A rs11515 462 160 14 454 125 9 1,442 0,608 3,420 1,313 0,998 1,729 
CD4 rs3213428 453 159 14 428 130 7 1,561 0,617 3,950 1,072 0,816 1,410 
INSR rs1051690 428 187 33 392 197 15 1,942 1,031 3,660 0,874 0,681 1,121 
INSR rs2860171 615 32 1 581 27 1 0,995 0,061 16,269 1,117 0,652 1,913 
GHR rs2973016 617 9 0 586 11 0 0,782 0,314 1,943 0,923 0,731 1,164 
 
 
A
 Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were 
resubmitted to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. 
B
 OR = odds ratio; CI = confidence interval. ORs were adjusted for sex and age. Only results for the co-dominant model are shown. Statistically significant 
results (p<0.05) are shown in bold. 
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Table7b. Logistic regression analysis for the selected SNPs in the miRNA sequences. Only the co-dominant model is shown. 
 
   
CASESA 
  
CONTROLSA 
 
OR HOMOZYGOTES 
 
OR HETEROZIGOTES 
Genes SNP Ref. WT/WT WT/MUT MUT/MUT WT/WT WT/ MUT MUT/MUT ORB LOW 95% UP 95% ORB LOW 95% UP 95% 
miR-608 rs4919510 448 190 19 397 194 17 0,930 0,468 1,840 0,846 0,660 1,085 
miR-492 rs2289030 573 68 7 529 70 4 1,714 0,479 6,130 0,867 0,603 1,248 
miR-196a-2 rs11614913 282 263 92 229 273 78 0,986 0,689 1,411 0,778 0,606 6,998 
miR-146a rs2910164 389 217 46 354 189 46 0,952 0,611 1,485 0,985 0,768 1,263 
miR-633 rs17759989 637 19 1 574 26 0 44044,0 undetermined 0,600 0,320 1,125 
miR-605 rs2043555 360 249 33 337 204 33 0.999 0,596 1,675 1,197 0,651 1,529 
miR-499 rs3746444 348 171 36 298 168 10 2,810 1,355 5,824 0,863 0,658 1,130 
miR-631 rs5745925 581 64 6 485 67 1 4,957 0,577 42,531 0,801 0,553 1,139 
 
 
 
 
A
 Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were 
resubmitted to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. 
B
 OR = odds ratio; CI = confidence interval. ORs were adjusted for sex and age. Only results for the co-dominant model are shown. Statistically significant 
results (p<0.05) are shown in bold. 
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Table8. Logistic regression analysis for the SNPs in CD86 and INSR genes: Spain population. Only the co-dominant model is 
shown. 
 
 
  
 
CASESA 
 
CONTROLSA OR 
HOMOZYGOTES 
OR 
HETEROZIGOTES 
Genes SNP WT/WT WT/MUT MUT/MUT WT/WT WT/ MUT MUT/MUT ORB LOW 95% 
UP 
95% OR
B
 
LOW 
95% 
UP 
95% 
              
CD86 rs17281995 238 82 12 181 67 7 1,34 0,51 3,48 0,97 0,66 1,42 
 
             
INSR rs1051690 232 88 17 195 75 4 3,20 1,05 9,78 1,00 0,69 1,44 
              
 
 
 
 
A
 Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were 
resubmitted to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. 
B
 OR = odds ratio; CI = confidence interval. ORs were adjusted for sex and age. Only results for the co-dominant model are shown. Statistically significant 
results (p<0.05) are shown in bold. 
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Table9. Logistic regression analysis for the SNPs in CD86 and INSR genes: Italian population. Only the co-dominant model is 
shown. 
 
  
 
CASESA 
 
CONTROLSA OR 
HOMOZYGOTES 
OR 
HETEROZIGOTES 
Genes SNP WT/WT WT/MUT MUT/MUT WT/WT WT/ MUT MUT/MUT ORB LOW 95% 
UP 
95% OR
B
 
LOW 
95% 
UP 
95% 
              
CD86 rs17281995 157 64 3 334 107 8 0,30 0,04 2,32 1,18 0,68 2,02 
 
             
INSR rs1051690 171 44 8 330 107 8 1,74 0,29 10,48 1,09 0,54 2,24 
              
 
 
 
A
 Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were 
resubmitted to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. 
B
 OR = odds ratio; CI = confidence interval. ORs were adjusted for sex and age. Only results for the co-dominant model are shown. Statistically significant 
results (p<0.05) are shown in bold. 
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Table10. Logistic regression analysis for the SNPs in CD86 and INSR genes: German population. Only the co-dominant model is 
shown. 
 
  
 
CASESA 
 
CONTROLSA OR 
HOMOZYGOTES 
OR 
HETEROZIGOTES 
Genes SNP WT/WT WT/MUT MUT/MUT WT/WT WT/ MUT MUT/MUT ORB LOW 95% 
UP 
95% OR
B
 
LOW 
95% 
UP 
95% 
              
CD86 rs17281995 853 329 29 921 310 31 1,01 0,60 1,69 1,15 0,95 1,37 
 
             
INSR rs1051690 845 349 36 887 343 45 0,84 0,54 1,31 1,10 0,90 1,30 
              
 
 
 
A
 Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were 
resubmitted to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. 
B
 OR = odds ratio; CI = confidence interval. ORs were adjusted for sex and age. Only results for the co-dominant model are shown. Statistically significant 
results (p<0.05) are shown in bold. 
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Table11. General logistic regression analysis for the SNPs in CD86 and INSR genes: Czech Republic, Spain, Italian, and German 
populations. Only the co-dominant model is shown. 
 
  
 
CASESA 
 
CONTROLSA OR 
HOMOZYGOTES 
OR 
HETEROZIGOTES 
Genes SNP WT/WT WT/MUT MUT/MUT WT/WT WT/ MUT MUT/MUT ORB LOW 95% 
UP 
95% OR
B
 
LOW 
95% 
UP 
95% 
              
CD86 rs17281995 1684 620 68 1870 598 54 1,40 1,02 2,01 1,15 1,01 1,31 
 
       
   
   
INSR rs1051690 1651 661 92 1776 718 70 1,41 1,01 1,94 0,99 0,87 1,12 
              
 
 
 
A
 Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were 
resubmitted to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left blank. 
B
 OR = odds ratio; CI = confidence interval. ORs were adjusted for sex and age. Only results for the co-dominant model are shown. Statistically significant 
results (p<0.05) are shown in bold. 
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